Document:

Exhibit 10.75

 

*** TEXT OMITTED AND SUBMITTED PURSUANT TO CONFIDENTIAL TREATMENT REQUEST

 

Final Execution Draft

May 21, 2013

Master Manufacturing Services Agreement

 

Master Manufacturing Services Agreement

 

May 21, 2013

 

 

Table of Contents

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    	
 
    
	
ARTICLE 1   STRUCTURE OF AGREEMENT AND INTERPRETATION  
    	
1
    
	
 
    	
 
    	
 
    
	
1.1
    	
Master Agreement
    	
1
    
	
 
    	
 
    	
 
    
	
1.2
    	
Product Agreements
    	
1
    
	
 
    	
 
    	
 
    
	
1.3
    	
Definitions
    	
2
    
	
 
    	
 
    	
 
    
	
1.4
    	
Currency
    	
9
    
	
 
    	
 
    	
 
    
	
1.5
    	
Sections and Headings
    	
9
    
	
 
    	
 
    	
 
    
	
1.6
    	
Singular Terms
    	
9
    
	
 
    	
 
    	
 
    
	
1.7
    	
Appendix 1 and Exhibits
    	
9
    
	
 
    	
 
    	
 
    
	
ARTICLE 2   PATHEON’S MANUFACTURING SERVICES  
    	
9
    
	
 
    	
 
    	
 
    
	
2.1
    	
Manufacturing Services
    	
9
    
	
 
    	
 
    	
 
    
	
2.2
    	
Active Material Yield
    	
12
    
	
 
    	
 
    	
 
    
	
ARTICLE 3   CLIENT’S OBLIGATIONS
    	
14
    
	
 
    	
 
    	
 
    
	
3.1
    	
Payment
    	
14
    
	
 
    	
 
    	
 
    
	
3.2
    	
Active Materials and   Qualification of Additional Sources of Supply
    	
14
    
	
 
    	
 
    	
 
    
	
ARTICLE 4   INITIAL PRICING AND ADJUSTMENTS
    	
15
    
	
 
    	
 
    	
 
    
	
4.1
    	
Initial Pricing
    	
15
    
	
 
    	
 
    	
 
    
	
4.2
    	
Price Adjustments
    	
15
    
	
 
    	
 
    	
 
    
	
4.3
    	
Price Adjustments —   Current Year Pricing
    	
17
    
	
 
    	
 
    	
 
    
	
4.4
    	
Adjustments Due to   Technical Changes
    	
18
    
	
 
    	
 
    	
 
    
	
4.5
    	
Multi-Country Packaging   Requirements
    	
19
    
	
 
    	
 
    	
 
    
	
4.6
    	
Audits
    	
19
    
	
 
    	
 
    	
 
    
	
ARTICLE 5   ORDERS, SHIPMENT, INVOICING, PAYMENT
    	
19
    
	
 
    	
 
    	
 
    
	
5.1
    	
Orders and Forecasts
    	
19
    
	
 
    	
 
    	
 
    
	
5.2
    	
Reliance by Patheon
    	
20
    
	
 
    	
 
    	
 
    
	
5.3
    	
Batch Order Quantities
    	
21
    
	
 
    	
 
    	
 
    
	
5.4
    	
Delivery
    	
22
    
	
 
    	
 
    	
 
    
	
5.5
    	
Invoices and Payment
    	
22
    
	
 
    	
 
    	
 
    
	
ARTICLE 6   PRODUCT CLAIMS AND RECALLS
    	
22
    
	
 
    	
 
    	
 
    
	
6.1
    	
Product Claims
    	
22
    
	
 
    	
 
    	
 
    
	
6.2
    	
Product Recalls and   Returns
    	
23
    
	
 
    	
 
    	
 
    
	
6.3
    	
Patheon’s   Responsibility for Defective and Recalled Products
    	
24
    

 

ii

 

Table of Contents

(Continued)

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    	
 
    
	
6.4
    	
Disposition of   Defective or Recalled Products
    	
25
    
	
 
    	
 
    	
 
    
	
6.5
    	
Healthcare Provider or   Patient Questions and Complaints
    	
25
    
	
 
    	
 
    	
 
    
	
6.6
    	
Remedies
    	
26
    
	
 
    	
 
    	
 
    
	
ARTICLE 7   CO-OPERATION
    	
26
    
	
 
    	
 
    	
 
    
	
7.1
    	
Quarterly Review
    	
26
    
	
 
    	
 
    	
 
    
	
7.2
    	
Authorities
    	
26
    
	
 
    	
 
    	
 
    
	
7.3
    	
Records and Accounting   by Patheon
    	
26
    
	
 
    	
 
    	
 
    
	
7.4
    	
Inspection
    	
27
    
	
 
    	
 
    	
 
    
	
7.5
    	
Access
    	
27
    
	
 
    	
 
    	
 
    
	
7.6
    	
Notification of   Regulatory Inspections
    	
28
    
	
 
    	
 
    	
 
    
	
7.7
    	
Reports
    	
28
    
	
 
    	
 
    	
 
    
	
7.8
    	
Regulatory Filings
    	
29
    
	
 
    	
 
    	
 
    
	
ARTICLE 8   TERM AND TERMINATION
    	
29
    
	
 
    	
 
    	
 
    
	
8.1
    	
Initial Term
    	
29
    
	
 
    	
 
    	
 
    
	
8.2
    	
Termination for Cause
    	
30
    
	
 
    	
 
    	
 
    
	
8.3
    	
Product Discontinuation
    	
31
    
	
 
    	
 
    	
 
    
	
8.4
    	
Obligations on   Termination
    	
31
    
	
 
    	
 
    	
 
    
	
ARTICLE 9   REPRESENTATIONS, WARRANTIES AND COVENANTS
    	
32
    
	
 
    	
 
    	
 
    
	
9.1
    	
Authority
    	
32
    
	
 
    	
 
    	
 
    
	
9.2
    	
Client Representations,   Warranties, and Covenants
    	
32
    
	
 
    	
 
    	
 
    
	
9.3
    	
Patheon   Representations, Warranties, and Covenants
    	
33
    
	
 
    	
 
    	
 
    
	
9.4
    	
Debarred Persons
    	
34
    
	
 
    	
 
    	
 
    
	
9.5
    	
Permits
    	
34
    
	
 
    	
 
    	
 
    
	
9.6
    	
No Warranty
    	
35
    
	
 
    	
 
    	
 
    
	
ARTICLE 10   REMEDIES AND INDEMNITIES
    	
35
    
	
 
    	
 
    	
 
    
	
10.1
    	
Consequential Damages
    	
35
    
	
 
    	
 
    	
 
    
	
10.2
    	
Limitation of Liability
    	
35
    
	
 
    	
 
    	
 
    
	
10.3
    	
Indemnification by   Patheon
    	
35
    
	
 
    	
 
    	
 
    
	
10.4
    	
Indemnification by   Client
    	
36
    
	
 
    	
 
    	
 
    
	
10.5
    	
Indemnification   Procedure
    	
36
    
	
 
    	
 
    	
 
    
	
10.6
    	
Reasonable Allocation   of Risk
    	
38
    

 

iii

 

Table of Contents

(Continued)

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    	
 
    
	
ARTICLE 11   CONFIDENTIALITY
    	
38
    
	
 
    	
 
    	
 
    
	
11.1
    	
Confidentiality   Agreement
    	
38
    
	
 
    	
 
    	
 
    
	
11.2
    	
Confidential   Information
    	
39
    
	
 
    	
 
    	
 
    
	
11.3
    	
Exceptions to Confidentiality
    	
39
    
	
 
    	
 
    	
 
    
	
11.4
    	
Disclosure
    	
39
    
	
 
    	
 
    	
 
    
	
11.5
    	
Notification
    	
41
    
	
 
    	
 
    	
 
    
	
11.6
    	
Remedies
    	
41
    
	
 
    	
 
    	
 
    
	
ARTICLE 12   DISPUTE RESOLUTION
    	
41
    
	
 
    	
 
    	
 
    
	
12.1
    	
Dispute Resolution
    	
41
    
	
 
    	
 
    	
 
    
	
ARTICLE 13   MISCELLANEOUS
    	
41
    
	
 
    	
 
    	
 
    
	
13.1
    	
Intellectual Property   Ownership and Licenses
    	
41
    
	
 
    	
 
    	
 
    
	
13.2
    	
No Implied Rights
    	
43
    
	
 
    	
 
    	
 
    
	
13.3
    	
Insurance
    	
43
    
	
 
    	
 
    	
 
    
	
13.4
    	
Independent Contractors
    	
43
    
	
 
    	
 
    	
 
    
	
13.5
    	
No Waiver
    	
43
    
	
 
    	
 
    	
 
    
	
13.6
    	
Assignment
    	
44
    
	
 
    	
 
    	
 
    
	
13.7
    	
Force Majeure
    	
44
    
	
 
    	
 
    	
 
    
	
13.8
    	
Additional Product
    	
45
    
	
 
    	
 
    	
 
    
	
13.9
    	
Notices
    	
45
    
	
 
    	
 
    	
 
    
	
13.10
    	
Severabilitv
    	
46
    
	
 
    	
 
    	
 
    
	
13.11
    	
Entire Agreement
    	
46
    
	
 
    	
 
    	
 
    
	
13.12
    	
Other Terms,
    	
46
    
	
 
    	
 
    	
 
    
	
13.13
    	
No Third Party Benefit   or Right
    	
47
    
	
 
    	
 
    	
 
    
	
13.14
    	
Execution in   Counterparts
    	
47
    
	
 
    	
 
    	
 
    
	
13.15
    	
Further Assurances
    	
47
    
	
 
    	
 
    	
 
    
	
13.16
    	
Export Control
    	
47
    
	
 
    	
 
    	
 
    
	
13.17
    	
Waiver
    	
47
    
	
 
    	
 
    	
 
    
	
13.18
    	
Construction
    	
47
    
	
 
    	
 
    	
 
    
	
13.19
    	
Use of Client Name
    	
48
    
	
 
    	
 
    	
 
    
	
13.20
    	
Governing Law;   Jurisdiction; Venue; Service
    	
48
    

 

iv

 

	
Appendix   1
    	
Form of   Product Agreement
    
	
 
    	
 
    
	
Exhibit A
    	
Form of   Quarterly Active Materials Inventory Report
    
	
 
    	
 
    
	
Exhibit B
    	
Form of   Annual Active Materials Inventory Reconciliation and Calculation of Actual   Annual Yield
    
	
 
    	
 
    
	
Exhibit C
    	
Example   of Price Adjustment Due to Currency Fluctuation
    

 

v

 

MASTER MANUFACTURING SERVICES AGREEMENT

 

THIS MASTER MANUFACTURING SERVICES AGREEMENT (the “Agreement”) is made as of May 21, 2013 (the “Effective Date”)

 

B E T W E E N:

 

PATHEON PHARMACEUTICALS INC 
  a corporation existing under the laws of the State of Delaware

 

(“Patheon”),

 

- and -

 

SALIX PHARMACEUTICALS, INC
  a corporation existing under the laws of the State of California

 

(“Client”).

 

THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations assumed herein, and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged by each party), and intending to be legally bound, the parties agree as follows:

 

ARTICLE 1
 STRUCTURE OF AGREEMENT AND INTERPRETATION

 

1.1                                                                               Master Agreement.

 

This Agreement establishes the general terms and conditions under which Patheon or any Affiliate of Patheon may perform Manufacturing Services for Client or any Affiliate of Client.  This “master’ form of agreement is intended to allow the parties, or any of their Affiliates, to contract for the manufacture of multiple Products through Patheon’s global network of manufacturing sites through the issuance of site specific Product Agreements without having to re-negotiate the basic terms and conditions contained herein.

 

1.2                                                                               Product Agreements.

 

This Agreement is structured so that a Product Agreement may be entered into by the parties for the manufacture of a particular Product or multiple Products at a Patheon manufacturing site.  Each Product Agreement will be governed by and subject to the terms and conditions of this Agreement except to the extent the parties to the Product Agreement expressly and by explicit reference modify the terms and conditions of this Agreement in the Product Agreement.  Unless otherwise agreed by the parties, each Product Agreement will be in the general form and contain the information set forth in Appendix 1 hereto.

 

 

1.3                                                                               Definitions.

 

The following terms, unless the context otherwise requires, have the respective meanings set out below and grammatical variations of these terms have corresponding meanings:

 

“Active Materials”, “Active Pharmaceutical Ingredients” or “API” means the materials listed and identified as such in a Product Agreement on Schedule D thereto;

 

“Active Materials Credit Value” means the value of the Active Materials for certain purposes of this Agreement, as set forth in a Product Agreement on Schedule D thereto;

 

“Actual Annual Yield” or “AAY” has the meaning specified in Section 2,2(a);

 

“Affiliate” of an entity means:

 

(a)                                 a business entity which owns, directly or indirectly, a controlling interest in such entity; or

 

(b)                                 a business entity which is controlled by such entity, either directly or indirectly; or

 

(c)                                  a business entity, the controlling interest of which is owned, either directly or indirectly, by a person or entity that also owns, directly or indirectly, a controlling interest in such first entity;

 

For this definition, “control” means the ownership of shares carrying at least a majority of the votes for the election of the directors of a corporation.

 

“Annual Product Review Report” means the annual product review report prepared by Patheon as described in Title 21 of the United States Code of Federal Regulations, Section 211.180(e);

 

“Annual Report” means, in respect of a Product, the annual report to the FDA prepared by Client regarding the Product as described in Title 21 of the United States Code of Federal Regulations, Section 314.81(b)(2);

 

“Annual Volume Tier” means one of the tiers set forth in Schedule B to a Product Agreement, showing the Price that would apply with respect to a given quantity of Product;

 

“Applicable Laws” means the applicable Laws of the jurisdictions where the Products are manufactured, distributed, and marketed as these are agreed and understood by the parties in this Agreement;

 

2

 

“Authority” means any governmental or regulatory authority, department, body or agency or any court, tribunal, bureau, commission or other similar body, whether federal, state, provincial, county or municipal;

 

“Batch Order Quantity” means the minimum number of batches of a Product to be produced during the same cycle of manufacturing as set forth in a Product Agreement on Schedule B thereto;

 

“Bill Back Items” means the expenses for all third party supplier fees for the purchase or use of columns, standards, tooling, non-standard pallets, powered air purifying respirator or personal protective equipment suits (where applicable), RFID tags and supporting equipment, and other project-specific items necessary for Patheon to perform the Manufacturing Services, and which are not included as Active Materials or Components;

 

“Breach Notice” has the meaning specified in Section 8.2(a);

 

“Business Day” means a day other than a Saturday, Sunday or a day that is a statutory holiday in the States of Ohio or North Carolina or in the jurisdiction where the Manufacturing Site is located;

 

“cGMPs” means, as applicable, current good manufacturing practices as described in:

 

(a)                                 Division 2 of Part C of the Food and Drug Regulations (Canada);

 

(b)                                 Parts 210 and 211 of Title 21 of the United States’ Code of Federal Regulations; and

 

(c)                                  EC Directive 2003/94/EC and Volume 4 of the European Commission’s Rules governing medicinal products in the European Union,

 

together with the latest Health Canada, FDA and EMA guidance documents pertaining to manufacturing and quality control practice, all as updated, amended and revised from time to time;

 

“Client Indemnitees” has the meaning specified in Section 10.3;

 

“Client Intellectual Property” means (a) Intellectual Property generated, discovered or developed by Client and (b) Product IP.

 

“Client Property” has the meaning specified in Section 8.4(d);

 

“Components” means, collectively, all packaging components, raw materials, ingredients, and other materials (including labels, product inserts and other labelling for the Products) required to manufacture the Products in accordance with the Specifications, other than the Active Materials and Bill Back Items;

 

3

 

“Confidentiality Agreement” means the Confidentiality Agreement between Patheon and Client dated January 25, 2005, as amended April 29, 2009;

 

“Confidential Information” means any and all information or material that has been or is provided or communicated to the Receiving Party by or on behalf of the Disclosing Party (including by a third party) pursuant to this Agreement or in connection with the transactions contemplated hereby or any discussions or negotiations with respect thereto; any data, ideas, concepts or techniques contained therein; and any modifications thereof or derivations therefrom. Confidential Information includes information or material disclosed orally, visually, electronically, in writing, by delivery of materials containing Confidential Information or in any other form now known or hereafter invented;

 

“Courts” has the meaning specified in Section 13.20;

 

“Crofelemer Product” means “Product” as defined in the Crofelemer Product Agreement between the parties dated as of May 21, 2013;

 

“Deficiency Notice” has the meaning specified in Section 6.1(a);

 

“Delivery Date” means the date scheduled for shipment of Product under a Firm Order as set forth in Section 5.1(d);

 

“Disclosed Information” means “Information” as such term is defined in the Confidentiality Agreement;

 

“Disclosing Party” has the meaning specified in Section 11.2;

 

“Dispute” has the meaning set forth in Section 12.1;

 

“EMA” means the European Medicines Agency and any successor Authority;

 

“Excluded Lists” means the Department of Health and Human Service’s List of Excluded Individuals/Entities and the General Services Administration’s Lists of Parties Excluded from Federal Procurement and Non-Procurement Programs;

 

“FDA” means the United States Food and Drug Administration and any successor Authority;

 

“FFDCA” has the meaning specified in Section 9.3(b);

 

“Firm Orders” has the meaning specified in Section 5.1(b);

 

“Force Majeure Event” has the meaning specified in Section 13.7;

 

“Government Approval” means any and all approvals, licenses, registrations or authorizations of Regulatory Authorities necessary for the manufacture of Product

 

4

 

in the Territory or for distribution or sale in the Territory and the performance of the other activities contemplated in this Agreement;

 

“Health Canada” means the section of the Canadian Government known as Health Canada and includes, among other departments, the Therapeutic Products Directorate and the Health Products and Food Branch Inspectorate and any successor Authorities;

 

“Indemnification Claim Notice” has the meaning specified in Section 10.5(a);

 

“Indemnified Party” has the meaning specified in Section 10.5(a);

 

“Indemnifying Party” has the meaning specified in Section 10.5(a);

 

“Information” means any information, data, computer program, device, trade secret, method, know-how, process, technique or the like, whether or not written or otherwise fixed in any form or medium, regardless of the media on which it is contained and whether or not patentable or copyrightable;

 

“Initial Product Term” has the meaning specified in Section 8.1.

 

“Initial Set Exchange Rate” means as of the effective date of a Product Agreement, the initial exchange rate set forth in the Product Agreement to convert one unit of the billing currency into the Manufacturing Site local currency, calculated as the daily average interbank exchange rate for conversion of one unit of the billing currency into the Manufacturing Site local currency during the 90 day period immediately preceding the effective date as published by OANDA.com “The Currency Site” under the heading “FxHistory: historical currency exchange rates” at www.OANDA.com/convert/fxhistorv;

 

“Initial Term” has the meaning specified in Section 8.1;

 

“Intellectual Property” means any and all intellectual property rights of whatever kind or nature and includes, without limitation, rights in patents, patent applications, formulae, trademarks, trademark applications, trade-names, Inventions, copyrights, industrial designs, trade secrets, and know how;

 

“Invention” means any innovation, improvement, development or discovery;

 

“Inventory” means all inventories of Components and work-in-process produced or held by Patheon for the manufacture of the Products but, for clarity, does not include the Active Materials or Bill Back Items;

 

“Joint Intellectual Property” means Intellectual Property generated, discovered or developed jointly by Patheon and Client, excluding the Product IP;

 

“Joint Invention Patents” has the meaning specified in Section 13.1(d)(iii);

 

5

 

“Laws” means all laws, statutes, ordinances, regulations, rules, by-laws, judgments, decrees or orders of any Authority;

 

“Losses” has the meaning specified in Section 10.3;

 

“Manufacturing Services” means the manufacturing, validation, quality control, quality assurance, stability testing, laboratory analysis, packaging, and related services, as set forth in this Agreement, required to manufacture and release Product or Products using the Active Materials, Components, and Bill Back Items;

 

“Manufacturing Site” means the facility owned and operated by Patheon where the Manufacturing Services are to be performed, as identified in the relevant Product Agreement;

 

“Materials” means all Components and Bill Back Items required to manufacture the Products in accordance with the Specifications, other than (for the avoidance of doubt) the Active Materials;

 

“Maximum Credit Value” means the maximum value of Active Materials that may be credited by Patheon under a Product Agreement, as set forth in the Product Agreement on Schedule D thereto;

 

“Patheon Competitor” means a business that derives greater than 50% of its revenues from performing contract pharmaceutical development or commercial manufacturing services for third parties;

 

“Patheon Indemnitees” has the meaning specified in Section 10.4;

 

“Patheon Intellectual Property” means Intellectual Property (a) generated, discovered or developed by Patheon before performing any Manufacturing Services or receiving any Confidential Information from Client under this Agreement or (b) generated, discovered or developed by Patheon while or as a result of performing the Manufacturing Services, but excluding for the purpose of this clause (b) only any Product IP and any Joint Intellectual Property;

 

“PPI” has the meaning specified in Section 4.2(a);

 

“Product IP” means Intellectual Property generated, discovered, or developed by Patheon, either alone or jointly with Client (or, in the case of Crofelemer Product, jointly with Glenmark Pharma), while or as a result of performing the Manufacturing Services (or while performing manufacturing services for Glenmark Pharma with respect to Crofelemer Product), that has particular application to, or is otherwise related to, the development, manufacture, use, marketing or sale of, or that is in any way dependent upon, any Active Material or Product;

 

6

 

“Price” means the price measured in US Dollars to be charged by Patheon for performing the Manufacturing Services under a particular Product Agreement, and includes the cost of Components, certain cost items as set forth on Schedule B to the relevant Product Agreement, and annual stability testing costs as set forth on Schedule C to the relevant Product Agreement;

 

“Product Agreement” means an agreement between Patheon (as defined therein) and Client (as defined therein) issued under this Agreement in the form set forth in Appendix 1 (including Schedules A to 0) under which Patheon (as defined therein) is to perform Manufacturing Services at a particular Manufacturing Site;

 

“Product(s)” means the product(s) listed in a Product Agreement on Schedule A thereto; “Product Claims” has the meaning specified in Section 6.3(c);

 

“Product Term” has the meaning specified in Section 8.1;

 

“Quality Agreement” means the agreement between the parties entering into a Product Agreement that sets out the quality assurance standards for the Manufacturing Services to be performed under such Product Agreement;

 

“Quantity Converted” has the meaning specified in Section 2.2(a).

 

“Quantity Dispensed” has the meaning specified in Section 2.2(a).

 

“Quantity Received” has the meaning specified in Section 2.2(a).

 

“Recall” has the meaning specified in Section 6,2(a);

 

“Receiving Party” has the meaning set forth in Section 11.2;

 

“Recipients” has the meaning set forth in Section 11.2;

 

“Regulatory Authority” means the FDA, EMA, and Health Canada and any other Authority competent to regulate the manufacture, sale or marketing of pharmaceutical products, including the Products, in the Territory;

 

“Remediation Period” has the meaning specified in Section 8.2(a);

 

“Required Percentage” has the meaning specified in Section 2.1;

 

“Required Period” has the meaning specified in Section 2.1;

 

“RFID” means Radio Frequency Identification Devices which (at present or in the future) may be affixed to Products, Active Materials, or Materials to assist in inventory control, tracking, and identification;

 

“Set Exchange Rate” means the exchange rate to convert one unit of the billing currency into the Manufacturing Site local currency for each Year, calculated as the average daily interbank exchange rate for conversion of one unit of the billing

 

7

 

currency into the Manufacturing Site local currency during the full year period (October 1st [preceding year] to September 30th), as published by OANDA.com “The Currency Site” under the heading “FxHistory: historical currency exchange rates” at www.OANDA.com/convertifxhistory;]

 

“Shortfall” has the meaning specified in Section 2.2(b);

 

“Specifications” means the file, for each Product, which is given by Client or an Affiliate of Client to Patheon in accordance with the procedures listed in a Product Agreement on Schedule A thereto and which contains documents relating to each Product, including, without limitation:

 

(a)                                 specifications for Active Materials and Components;

 

(b)                                 manufacturing specifications, directions, and processes;

 

(c)                                  storage requirements;

 

(d)                                 all environmental, health and safety information for each Product including material safety data sheets; and

 

(e)                                  the finished Product specifications, packaging specifications and shipping requirements for each Product;

 

all as updated, amended and revised from time to time by Client in accordance with the terms of this Agreement and the applicable Product Agreement;

 

“Target Yield” has the meaning specified in Section 2.2(a);

 

“Target Yield Determination Batches” has the meaning specified in Section 2.2(a);

 

“Term” has the meaning specified in Section 8.1;

 

“Territory” means the countries comprising the geographic area described in a Product Agreement where Products manufactured by Patheon are to be distributed, marketed and otherwise exploited by or on behalf of Client;

 

“Third Party Claims” has the meaning specified in Section 10.3; “Third Party Rights” means the Intellectual Property of any third party;

 

“United States” means the United States of America, including its territories and possessions, including the District of Columbia and Puerto Rico;

 

“Year” means each consecutive period of 12 consecutive calendar months commencing on January 1 and ending on December 31, except that the first Year of the Term will be the period from the Effective Date up to and including December 31 of the same calendar year, and the last Year of the Term shall

 

8

 

commence on January 1 of the calendar year in which the Term ends and end on the last day of the Term.

 

1.4                                                                               Currency.

 

Unless otherwise agreed in a Product Agreement, all monetary amounts expressed in this Agreement are in United States Dollars (USD).

 

1.5                                                                               Sections and Headings.

 

The division of this Agreement into Articles, Sections, Subsections, an Appendix, and Exhibits, and the insertion of headings, are for convenience of reference only and will not affect the interpretation of this Agreement.  Unless otherwise indicated, any reference in this Agreement to an Article, Section, Subsection, clause, Appendix or Exhibit refers to the specified Article, Section, Subsection, clause, Appendix, or Exhibit to this Agreement.  In this Agreement, the terms “this Agreement”, “hereof’, “herein”, “hereunder” and similar expressions refer to this Agreement and not to any particular part, Section, Appendix or Exhibit of this Agreement.

 

1.6                                                                               Singular Terms.

 

Except as otherwise expressly stated or unless the context otherwise requires, all references to the singular will include the plural and vice versa.

 

1.7                                                                               Appendix 1 and Exhibits.

 

Appendix 1 and the following Exhibits are attached to, incorporated in, and form part of this Agreement:

 

	
Appendix   1
    	
Form of   Product Agreement (including Schedules A to D)
    
	
 
    	
 
    
	
Exhibit A
    	
Quarterly   Active Materials Inventory Report
    
	
 
    	
 
    
	
Exhibit B
    	
Report   of Annual Active Materials Inventory Reconciliation and Calculation of Actual   Annual Yield
    
	
 
    	
 
    
	
Exhibit C
    	
Example   of Price Adjustment Due to Currency Fluctuation
    

 

ARTICLE 2
 PATHEON’S MANUFACTURING SERVICES

 

2.1                                                                               Manufacturing Services.

 

Patheon will perform the Manufacturing Services for Products to be distributed and sold by Client in the Territory for the fees specified in Schedules B and C to the relevant Product Agreement.  Schedule B to each Product Agreement sets forth a list of cost items that are included in the Price for Products; all cost items that are not included in this list are excluded from the Price and are subject to additional fees to be paid by Client.  Patheon may amend the fees set out in Schedules B and C to a Product Agreement as set forth in Article 4.  Patheon will

 

9

 

perform the Manufacturing Services solely at the Manufacturing Site, unless otherwise agreed in writing by Client.  If the parties agree that Patheon will supply, and Client will purchase, at least a specified minimum percentage of Client’s requirements for a Product under a Product Agreement (the “Required Percentage”), then the applicable Product Agreement will set forth the Required Percentage and the time period during which the obligation will apply (the “Required Period”).  But this obligation (if any) will cease to apply to Client with respect to the Product if Patheon fails to remain in material compliance with its obligations under this Agreement or the applicable Product Agreement, or Patheon suspends performance under this Agreement or the applicable Product Agreement in connection with a Force Majeure Event or where Patheon is or will be prevented from supplying the Product as a result of the action of a Regulatory Authority.  Subject to its obligation (if any) to purchase the Required Percentage of a Product during the Required Period, Client may, at any time, obtain Product from a third party or may, at any time, qualify a third party to perform Manufacturing Services for the Product.  In performing the Manufacturing Services, Patheon and Client agree that:

 

(a)                                 Conversion of Active Materials and Components.  Patheon will convert Active Materials and Components into Products.

 

(b)                                 Quality Control and Quality Assurance.  Patheon will perform the quality control and quality assurance testing specified in the Quality Agreement. Batch review and release to Client will be the responsibility of Patheon’s quality assurance group.  Patheon will perform its batch review and release responsibilities in accordance with Patheon’s standard operating procedures.  Each time Patheon delivers Products to Client, it will give Client a certificate of analysis and certificate of compliance, in form and substance previously agreed between Patheon and Client, including a statement that the batch has been manufactured and tested in accordance with Specifications and cGMPs, together with any other documents that are required by the applicable Quality Agreement or are necessary for the distribution or sale of the Products in the Territory.  Client will have sole responsibility for the release of Products to the market, The form and style of batch documents, including, but not limited to, batch production records, lot packaging records, equipment set up control, operating parameters, and data printouts, raw material data, and laboratory notebooks will be the exclusive property of Patheon, provided that Product-related Information contained in those batch documents will be Client intellectual Property.

 

(c)                                  Components.  Patheon will purchase all Components at Patheon’s expense and as required by the Specifications.  Patheon will inspect and test all Components as required by the Specifications.

 

(d)                                 Stability Testing.  Patheon will conduct stability testing on the Products in accordance with the protocols set out in the Specifications for the separate fees and during the time periods set out in Schedule C to the relevant Product Agreement.  Patheon will not make any changes to these testing protocols without prior written approval from Client.  If a confirmed stability test failure occurs, Patheon will notify Client within one Business Day, after which Patheon and Client will jointly determine the proceedings and methods to be undertaken to

 

10

 

investigate the cause of the failure, including which party will bear the cost of the investigation.  Patheon will not be liable for these costs unless it has failed to perform the Manufacturing Services in accordance with the Specifications, cGMPs, Applicable Laws, and other requirements specified herein.  Patheon will give Client all stability test data and results at Client’s request.

 

(e)                                  Packaging.  Patheon will package the Products as set out in the Specifications.  Client will be responsible for the cost of artwork development.  Patheon will determine and imprint the batch numbers and expiration dates for each Product delivered.  The batch numbers and expiration dates will be affixed on the Products and on the shipping carton of each Product as outlined in the Specifications and as required by cGMPs and Applicable Laws. Client may, in its sole discretion, make changes to labels, product inserts, and other packaging for the Products.  Those changes will be submitted by Client to all applicable Authorities and other third parties responsible for the approval of the Products. Client will be responsible for the cost of labelling obsolescence when changes occur, as contemplated in Section 4.4(c).  Patheon’s name will not appear on the label or anywhere else on the Products unless: (i) required by any Applicable Laws; or (ii) Patheon consents in writing to the use of its name.

 

(f)                                   Active Materials.  At least 45 days before the scheduled production date for a Product, Client will deliver the Active Materials to the Manufacturing Site DDP (Incoterms 2010), at no cost to Patheon, in sufficient quantity to enable Patheon to manufacture the desired quantities of Product and to ship Product on the Delivery Date.  If the Active Materials are not received 45 days before the scheduled production date, Patheon may delay the shipment of Product by the same number of days as the delay in receipt of the Active Materials.  But if Patheon is unable to manufacture Product to meet this new shipment date due to prior third party production commitments, Patheon may delay the shipment by as much as an additional 10 days, or as otherwise agreed to in good faith by the parties.  Patheon’s sole remedy if Client fails to deliver Active Materials at least 45 days before the scheduled production date for a Product will be to delay shipment of the applicable Product as described in this Section 2.1(f), and this failure by Client will not be deemed a breach of this Agreement or any Product Agreement.  All shipments of Active Materials will be accompanied by certificate(s) of analysis from the Active Material manufacturer, as applicable, confirming the identity and purity of the Active Materials and its compliance with the Active Material specifications.  Title to the Active Materials will at all times remain the property of Client.  Patheon will inspect and test all Active Materials as required by the Specifications.

 

(g)                                  Use of Active Materials.  Patheon will use the Active Materials solely for manufacturing Product for Client and for related activities in accordance with the terms of this Agreement and the applicable Product Agreement and for no other purpose.

 

11

 

(h)                                 Storage of Active Materials.  Patheon at all times will store all Active Materials exclusively at the applicable Manufacturing Site, in a physically secure area under conditions that maintain their stability, integrity, and effectiveness and in accordance with the storage instructions provided therefor by Client.  Patheon will ensure that all Active Materials at all times will be free from damage, contamination, deterioration and adulteration and protected against theft.  Patheon will store all Active Materials by lot number and all Active Materials will be physically segregated from other goods and materials stored in the applicable Manufacturing Site.  Patheon will use all Active Materials on a first expired, first-out basis, and Patheon will not use any Active Materials after the applicable retest date thereof.

 

(i)                                     Notifications.  Patheon will promptly notify Client if any Active Materials are damaged, contaminated, adulterated, lost or stolen, deteriorate, or otherwise are rendered unusable after delivery to Patheon (whether before or after incorporation into work in progress).  If this occurs, the loss of Active Materials will be addressed under Section 2.2.

 

(j)                                    Bill Back Items.  Bill Back Items will be acquired by Patheon as required to perform the Manufacturing Services but charged to Client at Patheon’s cost plus a [***]% handling fee.

 

(k)                                 Product Rejection for Finished Product Specification Failure.  If the parties agree, after a full quality investigation by the parties in accordance with cGMP requirements, Applicable Laws, and the applicable Quality Agreement, that Patheon manufactured Product in accordance with the Specifications, the batch production record, Patheon’s standard operating procedures for manufacturing, cGMPs, Applicable Laws, and the other terms and conditions of this Agreement, and the batch or partial batch of Product does not meet a Specification, Client will pay Patheon [***]% of the Component cost and [***]% of the manufacturing labor cost directly incurred from manufacturing the non-conforming Product.  The API in the non-conforming Product will be included in the “Quantity Converted” for purposes of calculating the “Actual Annual Yield” under Section 2.2(a).

 

2.2                                                                               Active Material Yield.

 

(a)                                 Reporting.  Within 15 days after the end of each quarter of each Year, Patheon will give Client a quarterly inventory report of the Active Materials held by Patheon using the inventory report form set out in Exhibit A, which will contain the following information for the quarter:

 

“Quantity Received”:  The total quantity of Active Materials that complies with the Specifications and was received at the Manufacturing Site during the applicable quarter.

 

“Quantity Dispensed”:  The total quantity of Active Materials dispensed at the Manufacturing Site during the applicable quarter.  The Quantity Dispensed for

 

*** Confidential Treatment Requested

 

12

 

each applicable quarter is calculated by adding the Quantity Received during the applicable quarter to the inventory of Active Materials that complied with the Specifications held at the beginning of the applicable quarter, less the inventory of Active Materials that complied with the Specifications held at the end of the quarter.  The Quantity Dispensed during each applicable quarter will only include Active Materials received and dispensed in commercial manufacturing of Products and, for certainty, will not include any (i) Active Materials that must be retained by Patheon as samples, (ii) Active Materials contained in Product that must be retained as samples, (iii) Active Materials used in testing (if applicable), and (iv) Active Materials received or dispensed in technical transfer activities or development activities during the applicable quarter, including without limitation, any regulatory, stability, validation or test batches manufactured during the applicable quarter.

 

 

“Quantity Converted”: The total amount of Active Materials contained in the Products manufactured with the Quantity Dispensed during the applicable quarter (including any additional Products produced in accordance with Section 6.3(a) or 6.3(b)), delivered by Patheon, and not rejected, recalled or returned in accordance with Section 6.1 or 6.2 because of Patheon’s failure to perform the Manufacturing Services in accordance with Specifications, cGMPs, and Applicable Laws.

 

Within 30 days after the end of each Year, Patheon will give Client an annual reconciliation of Active Materials on the reconciliation report form set forth in Exhibit B, including the calculation of the “Actual Annual Yield” or “AAY” for the Product at the Manufacturing Site during the Year, which will be the percentage of the Quantity Dispensed that was converted to Products and will be calculated as follows:

 

Quantity Converted during the Year                                                                                                                      x                 100%

Quantity Dispensed during the Year

 

After Patheon has produced a minimum of 15 successful commercial production batches of Product at the Manufacturing Site and has produced commercial production batches for at least six months at the Manufacturing Site (collectively, the “Target Yield Determination Batches”), the parties will agree in writing on the target yield for such Product at the Manufacturing Site (each, a “Target Yield”).  The Target Yield will be revised annually to reflect the actual manufacturing experience as agreed to by the parties.

 

(b)                                 Shortfall Calculation.  If the Actual Annual Yield falls more than [***]% below the applicable Target Yield for a Product in a Year, then the shortfall for the Year (the “Shortfall”) will be calculated as follows:

 

Shortfall =[(Target Yield — [***]%) — AAY] * Active Materials Credit Value * Quantity Dispensed

 

*** Confidential Treatment Requested

 

13

 

(c)                                  Credit for Shortfall.  If there is a Shortfall for a Product in a Year, then Patheon will credit Client’s account for the amount of the Shortfall not later than 60 days after the end of the Year.

 

Each Shortfall and credit owed Client under this Section 2.2(c) will be summarized on the reconciliation report form set forth in Exhibit B.  Upon expiration or termination of a Product Agreement, any remaining credit owing under this Section 2.2 will be paid to Client.  The Annual Shortfall, if any, will be disclosed by Patheon on the reconciliation report form.

 

(d)                                 Maximum Credit.  Patheon’s liability for Active Materials calculated in accordance with this Section 2.2 for any Product in a Year under any Product Agreement will not exceed, in the aggregate, the Maximum Credit Value set forth in Schedule D to the Product Agreement.

 

(e)                                  No Material Breach.  For clarity (and without modification of the standards for determining material breach that would normally apply to this Agreement), the parties agree that, if the Actual Annual Yield is less than the Target Yield for a given Year, this fact will not by itself constitute a material breach of the Agreement by Patheon.

 

ARTICLE 3
 CLIENT’S OBLIGATIONS

 

3.1                                                                               Payment.

 

Client will pay Patheon for performing the Manufacturing Services according to the Prices specified in Schedules B and C to each Product Agreement. These Prices may be subject to adjustment under other parts of this Agreement.  Client will also pay Patheon for any Bill Back Items in accordance with Section 2,1(j).

 

3.2                                                                               Active Materials and Qualification of Additional Sources of Supply.

 

Client will, at its sole cost and expense, deliver the Active Materials to Patheon (in accordance with Section 2.1(f)) sufficient for Patheon to manufacture the desired quantities of Product. Patheon and Client will reasonably cooperate to permit the import of the Active Materials to the Manufacturing Site.  Client’s obligation will include obtaining the proper release of the Active Materials from the applicable customs agency and Regulatory Authority, as applicable.  Client or Client’s designated agent will be the “Importer of Record” for Active Materials imported to the Manufacturing Site.

 

If Client asks Patheon to qualify an additional source for the Active Material or any Component, Patheon will cooperate with Client to evaluate the Active Material or Component to be supplied by the additional source to determine if it is suitable for use in the Product.  The parties will agree on the scope of work to be performed by Patheon at Client’s cost.  For an Active Material, this work at a minimum will include:

 

14

 

(a)                                 laboratory testing to confirm the Active Material meets existing Specifications;manufacture of a GMP qualification batch of Product that will be placed on three months accelerated stability.

 

(b)                                 If applicable, manufacture of three full-scale validation batches that will be placed on concurrent stability (one batch may be the registration batch if manufactured at full scale).

 

Section 2.1(k) will apply to all Product manufactured using the newly approved Active Material or Component because of the limited material characterization that is performed on additional sources of supply.

 

ARTICLE 4
 INITIAL PRICING AND ADJUSTMENTS

 

4.1                                                                               Initial Pricing.

 

The tiered Price and annual stability Price for the Products for the first Year are listed in Schedules B and C to the relevant Product Agreement and are subject to the adjustments set forth in Sections 4.2 and 4.3.

 

4.2                                                                               Price Adjustments.

 

After the first Year of a Product Agreement, Patheon may adjust the Price for the Product Agreement effective January 1st of each Year as follows:

 

(a)                                 Manufacturing and Stability Testing Costs.  For Products manufactured in the United States, Patheon may adjust that portion of the Price attributable to Manufacturing Services (and not to Components) for inflation, based upon the preliminary number for any increase in the Producer Price Index pcu325412325412 for Pharmaceutical Preparation Manufacturing (“PPI”) published by the United States Department of Labor, Bureau of Labor Statistics in August of the preceding Year compared to the final number for the same month of the Year prior to that, unless the parties otherwise agree in writing.  On or about November 1st of each Year, Patheon will give Client a statement setting forth the calculation for the inflation adjustment to be applied in calculating the Price for the next Year.  For Products manufactured outside the United States, Patheon may similarly adjust the Price for inflation using an inflation index to be agreed by the parties in the Product Agreement.  The maximum Price adjustment under this Section 4.2(a) will not exceed the lesser of (i) the PPI (as published by the United States Department of Labor, Bureau of Labor Statistics in August of the preceding Year compared to the final number for the same month of the Year prior to that) and (ii) [***]%.

 

(b)                                 Component Costs.  If Patheon incurs an increase in Component costs during the Year, it may increase the Price for the next Year to pass through the additional Component costs.  If Patheon’s Component costs decrease during a Year, Client will have the right to require a decrease in the Price for the next Year to pass

 

*** Confidential Treatment Requested

 

15

 

through the reduced Component costs.  On or about November 1st of each Year, Patheon will give Client information about any increase (or decrease) in Component costs, which will be applied to the calculation of the Price for the next Year, which information, in the case of a cost increase, will reasonably demonstrate that the Price increase is justified.  But Patheon will not be required to give information to Client that is subject to obligations of confidentiality between Patheon and its suppliers.  If requested by Client, Patheon will use commercially reasonable efforts to obtain permission to disclose this information to Client, or, where applicable, will provide this information to Client with appropriate redactions

 

(c)                                  Pricing Basis.  Client acknowledges that the Price in any Year is quoted based upon the Batch Order Quantity and Annual Volume Tiers specified in Schedule B to the relevant Product Agreement.  The Price may be subject to change if the specified Batch Order Quantity changes or the quantity specified in the lowest specified Annual Volume Tier is not ordered in a Year.  For greater certainty, if Patheon and Client agree that the Batch Order Quantity or lowest Annual Volume Tier will not be ordered in a Year, whether as a result of a decrease in Client’s forecasts or otherwise, and, as a result of the reduction, Patheon demonstrates to Client that its costs to perform the Manufacturing Services or to acquire the Components for the Product will increase on a per-unit basis, and the amount of such increase, then Patheon may increase the Price by an amount sufficient to absorb the documented increased costs.  On or about November 1st of each Year, Patheon will give Client a statement setting forth the information to be applied in calculating those cost increases (if any) for the next Year, But Patheon will not be required to give information to Client that is subject to obligations of confidentiality between Patheon and its suppliers.  If requested by Client, Patheon will use commercially reasonable efforts to obtain permission to disclose this information to Client, or, where applicable, will provide this information to Client with appropriate redactions.

 

(d)                                 Adjustments Due to Currency Fluctuations.  If the parties agree in a Product Agreement to invoice in a currency other than the local currency for the Manufacturing Site, Patheon will adjust the Price to reflect currency fluctuations.  The adjustment will be calculated after all other annual Price adjustments under this Section 4.2 have been made.  The adjustment will proportionately reflect the increase or decrease, if any, in the Set Exchange Rate compared to the Set Exchange Rate established for the prior Year or the initial Set Exchange Rate, as the case may be.  An example of the calculation of the price adjustment (for a Canadian Manufacturing Site invoiced in USD) is set forth in Exhibit C.

 

(e)                                  Tier Pricing (if applicable).  The pricing in Schedule B to a Product Agreement is set forth in Annual Volume Tiers based upon Clients volume forecasts under Section 5.1.  Client will be invoiced during the Year at the unit price set forth in the applicable Annual Volume Tier based on the 12 month forecast provided in September of the previous Year.  Within 30 days after the end of each Year or of the termination of the Product Agreement, Patheon will send Client a

 

16

 

reconciliation of the actual volume of Product ordered by the Client during the Year with the pricing tiers.  If Client has overpaid during the Year, Patheon will issue a credit to the Client for the amount of the overpayment within 45 days after the earliest of (i) the end of the Year and (ii) termination of the Product Agreement.  If Client has underpaid during the Year, Patheon will issue an invoice to the Client under Section 5.5 for the amount of the underpayment within 45 days after the earliest of (i) the end of the Year and (ii) termination of the Product Agreement.  If Client disagrees with the reconciliation, the parties will work in good faith to resolve the disagreement amicably.  If the parties are unable to resolve the disagreement within 30 days of Client’s notification to Patheon of its disagreement, the matter will be resolved in accordance with Section 12.1.

 

For all Price adjustments under this Section 4.2, Patheon will deliver to Client on or about November 1st of each Year a revised Schedule B to each Product Agreement to be effective for Product delivered under such Product Agreement on or after the first day of the next Year.

 

4.3                                                                               Price Adjustments — Current Year Pricing.  During any Year, the Prices set out in Schedule B of a Product Agreement will be adjusted as follows:

 

(a)                                 Extraordinary Increases in Component Costs.  If, at any time, market conditions result in Patheon’s cost of Components being materially greater than normal forecasted increases, then Patheon will be entitled to an adjustment to the then-applicable Price for any affected Product to compensate Patheon for the increased Component costs.  Changes materially greater than normal forecasted increases will have occurred if: (i) the cost of a Component increases by [***]% of the cost for that Component upon which the most recent fee quote was based; or (ii) the aggregate cost for all Components required to manufacture a Product increases by [***]% of the total Component costs for the Product upon which the most recent fee quote was based.  If Component costs have been previously adjusted to reflect an increase in the cost of one or more Components, the adjustments set out in (i) and (ii) above will operate based on the last cost adjustment for the Components.

 

(b)                                 For a Price adjustment proposed under this Section 4.3, Patheon will deliver to Client a revised Schedule B to the Product Agreement and budgetary pricing information, adjusted Component costs or other documents reasonably sufficient to demonstrate that a Price adjustment is justified.  Patheon will have no obligation to deliver any supporting documents that are subject to obligations of confidentiality between Patheon and its suppliers.  But, if requested by Client, Patheon will use commercially reasonable efforts to obtain permission to disclose these documents to Client, or will provide these documents with appropriate redactions.  The revised Price will be effective for any Product delivered on or after the first day of the month following Client’s receipt of the revised Schedule B to the Product Agreement.

 

*** Confidential Treatment Requested

 

17

 

4.4                                                                               Adjustments Due to Technical Changes.

 

(a)                                 Amendments to Specifications Required by Applicable Laws.  If an amendment to the Specifications is required by Applicable Laws, Client may amend the Specifications unilaterally and in its sole discretion.  If this amendment will result in increased costs incurred by Patheon, then the parties will negotiate in good faith an appropriate adjustment to the Price on commercially reasonable terms to reflect the increased cost to Patheon.  If the parties are not able to mutually agree to the Price changes within 30 days (or such longer period as the parties may agree) and Patheon does not agree to implement the amendment at no increase in Price, then the dispute will be resolved in accordance with Section 12.1.

 

(b)                                 Other Amendments.  Amendments to the Specifications or the Quality Agreement requested by Client, other than those addressed in Section 4.4(a), will only be implemented following a technical and cost review.  If this amendment will result in increased costs incurred by Patheon, then the parties will negotiate in good faith an appropriate adjustment to the Price on commercially reasonable terms to reflect the increased cost to Patheon.  If the parties are not able to mutually agree to the Price adjustment within 30 days (or such longer period as the parties may agree) and Patheon does not agree to implement the amendment at no increase in Price, Client at its option may either (i) determine not to implement the amendment and there will be no adjustment to the Price, or (ii) terminate this Agreement or the applicable Product Agreement.  Client will notify Patheon of its election within five Business Days after the end of the 30-day period (or such longer period as the parties may agree).  If Client elects to terminate this Agreement or a Product Agreement pursuant to clause (ii) of the penultimate sentence, this Agreement or the Product Agreement, as applicable, will terminate ten days after the giving of the election notice.

 

(c)                                  Obsolete Inventory.  Client agrees to purchase, at Patheon’s cost (including all costs incurred by Patheon for the purchase and handling of the Inventory), all Inventory used under the previous Specifications or Quality Agreement and purchased or maintained by Patheon in order to fill current Firm Orders, if the Inventory can no longer be used to manufacture Product under the revised Specifications or Quality Agreement as proposed by Client.  Open purchase orders for Components no longer required under any revised Specifications that were placed by Patheon with suppliers in order to fill current Firm Orders will be cancelled where possible, and if the orders may not be cancelled without penalty, will be assigned to and satisfied by Client, unless these Components may be used by Patheon for some other purpose.

 

(d)                                 Patheon-Requested Amendments.  Amendments to the Specifications, the Quality Agreement, or the Manufacturing Site requested by Patheon will only be implemented following the written approval of Client.

 

18

 

4.5                                                                               Multi-Country Packaging Requirements.

 

If Client requests that Patheon perform Manufacturing Services for the Product for countries outside the Territory, then Client will inform Patheon of the packaging requirements for each new country and Patheon will prepare a quotation for consideration by Client of any additional costs for Components and Bill-Back Items and the change over fees for the Product destined for each new country.  The agreed additional packaging requirements and related packaging costs will be set out in a written amendment to the applicable Product Agreement.

 

4.6                                                                               Audits.  Client shall have the right to have an independent accounting firm of nationally recognized standing provided with access by Patheon during normal business hours, and upon reasonable prior written notice, to examine only those records of Patheon (and, if applicable, its Affiliates) as may be reasonably necessary to determine, with respect to any Year ending not more than three years prior to Client’s request, the correctness of any Price increase taken by Patheon.  Such examinations may not be conducted more than once in any 12-month period (unless a previous audit during such 12-month period revealed an overpayment by Client with respect to such period or an incorrect statement submitted by Patheon in respect of such period).  Results of such audit shall (a) be (i) limited to information relating to the Products, (ii) made available to both parties in writing, and (iii) subject to Article 11 and (b) not reveal any specific information of Patheon to Client other than (i) whether statements submitted by Patheon with respect to any increase in Price are true and correct, as the case may be, and (ii) the amount of any excess payment reimbursable to Client or any correction to statements submitted by Patheon under this Agreement, as the case may be. The determination of such accounting firm shall be final and binding as between the parties.  The cost of any such examination shall be borne by Client, unless the audit reveals a variance of more than 10% from the reported amounts for the period under examination, in which case Patheon shall bear the cost of the audit.  If such audit concludes that excess payments were made by Client during the period under examination, then Patheon shall reimburse to Client the amount of such excess payment within 60 days after the date on which such auditor’s written report is delivered to the parties.

 

ARTICLE 5
 ORDERS, SHIPMENT, INVOICING, PAYMENT

 

5.1                                                                               Orders and Forecasts.

 

(a)                                 Rolling 12 Month Forecast.  When each Product Agreement is executed, Client will give Patheon a non-binding 12 month forecast of the volume of Product that Client expects to order in the first 12 months of commercial manufacture under such Product Agreement.  This forecast will then be updated by Client on or before the fifteenth day of each month (or, at Client’s discretion, at any time from the eighth day of such month up to and including the twenty-second day of such month) on a rolling forward basis as contemplated by Section 5.1(b), as applicable.  The most recent 12 month forecast will prevail.  Client will update the forecast forthwith if it determines that the volumes estimated in the most recent forecast have changed by more than 20%.

 

19

 

(b)                                 Firm Orders.  Unless otherwise agreed in a Product Agreement, on a rolling basis during the term of this Agreement, Client will issue an updated 12 month forecast on or before the fifteenth day of each month (or, at Clients discretion, at any time from the eighth day of such month up to and including the twenty-second day of such month), which forecast will be non-binding except as set forth in this Section 5.1(b).  This forecast will start on the first day of the next month.  The first three months of this updated forecast will be considered binding firm orders.  Concurrent with the 12 month forecast, Client will issue a new firm written order in the form of a purchase order or otherwise (“Firm Order”) by Client to purchase and, when accepted by Patheon, for Patheon to manufacture and deliver the agreed quantity of the Products.  The delivery date will not be less than 90 days following the date that the Firm Order Is submitted.  Firm Orders submitted to Patheon will specify Client’s purchase order number, quantities by Product type, monthly delivery schedule, and any other elements necessary to ensure the timely manufacture and shipment of the Products.  The quantities of Products ordered in those written orders will be firm and binding on Client and may not be reduced by Client.

 

(c)                                  Three Year Forecast.  On or before the tenth day of May of each Year while a Product Agreement is in effect, Client will give Patheon a written non-binding three-year forecast, broken down by quarters for the second and third years of the forecast, of the volume of each Product Client then anticipates will be required to be manufactured and delivered to Client under each Product Agreement during the three-year period,

 

(d)                                 Acceptance of Firm Order.  Patheon will accept Firm Orders by sending an acknowledgement to Client within ten Business Days of its receipt of the Firm Order; provided that if no acknowledgement is sent by Patheon in the specified period, the Firm Order will be deemed to have been accepted by Patheon.  Patheon will be required to accept any Firm Order submitted by Client in accordance with Section 5.1(b).  But Patheon will not be required to accept a Firm Order submitted by Client pursuant to Section 5.1(b) if the quantity of Product specified in the Firm Order exceeds 100% of the quantity specified in the most recent 12 month forecast for the period to which the Firm Order relates. Patheon will use commercially reasonable efforts to accept Firm Orders up to [***]% of the quantity specified in the most recent 12 month forecast for the period to which the Firm Order relates.  The acknowledgement will include, subject to confirmation from the Client, the Delivery Date for the Product ordered, and Patheon will be required to deliver the Product on the Delivery Date, subject to the following sentence.  The Delivery Date may be amended by agreement of the parties or as set forth in Sections 2.1(f).

 

5.2                                                                               Reliance by Patheon.

 

(a)                                 Client understands and acknowledges that Patheon will rely on the Firm Orders and rolling forecasts submitted under Sections 5.1(a), and (b), in ordering the Components required to meet the Firm Orders.  In addition, Client understands

 

*** Confidential Treatment Requested

 

20

 

that to ensure an orderly supply of the Components, Patheon may want to purchase the Components in sufficient volumes to meet the production requirements for Products during part or all of the forecasted periods referred to in Section 5.1(a) and (b) or to meet the production requirements of any longer period agreed to by Patheon and Client.  Accordingly, Client authorizes Patheon to purchase Components to satisfy the Manufacturing Services requirements for Products for the first six months contemplated in the most recent forecast given by Client under Section 5.1(a) or (b), as the case may be.  Patheon may make other purchases of Components to meet Manufacturing Services requirements for longer periods if agreed to in writing by the parties.

 

(b)                                 If Client requests that Patheon manufacture launch quantities of a Product for which purchase of Components is not provided for by Section 5.2(a), then Client will give Patheon written authorization to order the necessary Components and, once the written authorization is accepted by Patheon, Components ordered in this manner will be deemed to be properly ordered by Patheon as though they were ordered under Section 5.2(a).

 

(c)                                  If Components properly ordered by Patheon under Firm Orders or this Section 5.2 are not included In finished Products manufactured for Client within six months after the forecasted month for which the purchases have been made (or for a longer period as the parties may agree) or if the Components have expired during the period, then Client will pay to Patheon its costs therefor (including all costs incurred by Patheon for the purchase and handling of the Components). But if these Components are used in Products subsequently manufactured for Client or in third party products manufactured by Patheon, Client will receive credit for any costs of those Components previously paid to Patheon by Client.

 

(d)                                 If Client fails to take possession or arrange for the destruction of Components within 12 months of purchase in quantities and on a schedule as contemplated by Section 5.2(a) or of finished Product within three months of batch release of finished Product to Client in accordance with and pursuant to a Firm Order, Patheon will notify Client of such fact, and Client will pay Patheon $[***] per pallet, per month thereafter for storing the Components or finished Product. Storage fees for Components or Product which contain controlled substances or require refrigeration will be charged at $[***] per pallet per month. Storage fees are subject to a one pallet minimum charge per month. Patheon may ship finished Product held by it longer than three months following batch release of the Finished Product to Client in accordance with and pursuant to a Firm Order to the Client at Client’s expense on 14 days’ prior written notice to the Client.

 

5.3                                                                               Batch Order Quantities.

 

Client may only order Manufacturing Services for batches of Products in multiples of the Batch Order Quantities as set out in Schedule B to a Product Agreement, unless otherwise agreed by the parties.

 

*** Confidential Treatment Requested

 

21

 

5.4                                                                               Delivery.

 

Shipments of Products will be made EXW (Incoterms 2010) Patheon’s Manufacturing Site as specified in the relevant Product Agreement or such other shipping point as the parties may agree in writing, unless otherwise agreed in a Product Agreement.  Risk of loss or of damage to Products will remain with Patheon until the Products are loaded onto the carrier’s vehicle for shipment at the shipping point, at which time risk of loss or damage will transfer to Client.  Patheon will, in accordance with Client’s instructions and as agent for Client, (a) arrange for shipping, to be paid by Client and at Client’s risk, and (b) at Client’s risk and expense, obtain any export license or other official authorization necessary to export the Products, Client will arrange for insurance and will select the freight carrier used by Patheon to ship Products and may monitor Patheon’s shipping and freight practices as they pertain to this Agreement.  Products will be transported in accordance with the Specifications.  Patheon will cooperate and provide assistance to Client or Client’s designee for purposes of obtaining any license or approval required for the import of Products into a country in the Territory.

 

5.5                                                                               Invoices and Payment.

 

Invoices will be sent by fax or email to the fax number or email address given by Client to Patheon in writing.  Invoices will be sent and dated when the Product is manufactured and released by Patheon to the Client.  Patheon will also submit to Client, with each shipment of Products, a duplicate copy of the invoice covering the shipment.  Patheon will also give Client an invoice covering storage of any Product under Section 5.2(d) of this Agreement.  Each invoice will, to the extent applicable, identify Client’s Manufacturing Services purchase order number, Product numbers, names and quantities, unit price, freight charges, and the total amount to be paid by Client.  Client will pay all undisputed invoices within 30 days of the date thereof.  Interest on undisputed past due accounts will accrue at 1% per month, which is equal to an annual rate of 12%.

 

ARTICLE 6
 PRODUCT CLAIMS AND RECALLS

 

6.1                                                                               Product Claims.

 

(a)                                 Product Claims.  Client has the right to reject any portion of any shipment of Products that deviates from the Specifications, cGMPs, Applicable Laws or other warranties or requirements set forth herein without invalidating any remainder of the shipment.  Client will inspect the Products manufactured by Patheon upon receipt and will give Patheon written notice (a “Deficiency Notice”) of all claims for Products that deviate from the Specifications, cGMPs, Applicable Laws or other warranties or requirements set forth herein within 45 days after Client’s receipt of such Product and full batch records therefor (or, in the case of any defects not reasonably susceptible to discovery upon receipt of the Product, within 45 days after discovery by Client, but not after the expiration date of the Product).  Should Client fail to give Patheon the Deficiency Notice within the applicable 45 day period, then the delivery will be deemed to have been accepted by Client on the 46th day after delivery or discovery, as applicable.  Patheon will not be liable

 

22

 

under Section 6.3(a) for any deviations for which it has not received notice within the applicable 45 day period.

 

(b)                                 Determination of Deficiency.  Upon receipt of a Deficiency Notice, Patheon will have ten days to advise Client by notice in writing that it disagrees with the contents of the Deficiency Notice.  Should Patheon fail to object to the Deficiency Notice on a timely basis, Patheon will be deemed to have accepted and agreed with the Deficiency Notice.  If Client and Patheon fail to agree within ten days after any Patheon notice to Client objecting to a Deficiency Notice as to whether any Products identified in the Deficiency Notice deviate from the Specifications, cGMPs, Applicable Laws or other warranties or requirements set forth herein, then the parties will mutually select an independent laboratory that is properly qualified to make the relevant determination to determine whether the Products deviate from the Specifications, cGMPs, Applicable Laws or other warranties or requirements set forth herein. The determination of the independent laboratory will be binding on the parties.  If the independent laboratory determines that any Products deviate from the Specifications, cGMPs, Applicable Laws, or other warranties or requirements set forth herein, Client may reject those Products in the manner contemplated in this Section 6.1 and Patheon will be responsible for the cost of the evaluation.  If the independent laboratory finds that none of the Products deviates from the Specifications, cGMPs, Applicable Laws or other warranties or requirements set forth herein, then (i) Client will be deemed to have accepted delivery of the Products on the 40th day after delivery (or, in the case of any defects not reasonably susceptible to discovery upon receipt of the Product, on the 40th day after discovery thereof by Client), (ii) the invoice for the Product will be deemed to be dated as of the date when the finding is made, and (iii) Client will be responsible for the cost of the evaluation.

 

(c)                                  Shortages.  Claims for shortages in the amount of Products shipped by Patheon will be dealt with by reasonable agreement of the parties.

 

6.2                                                                               Product Recalls and Returns.

 

(a)                                 Records and Notice.  Patheon and Client will each maintain records necessary to permit a Recall of any Products delivered to Client or customers of Client.  Each party will promptly notify the other by telephone (to be confirmed in writing) of any information which might affect the marketability, safety or effectiveness of the Products or which might result in the Recall or seizure of the Products.  Upon receiving this notice or upon this discovery, each party will stop making any further shipments of any Products in its possession or control until a decision has been made whether a Recall or some other corrective action is necessary. The decision to initiate a Recall or to take some other corrective action, if any, will be made and implemented by Client.  “Recall” will mean any action (i) by Client to recover title to or possession of quantities of the Products sold or shipped to third parties (including, without limitation, the voluntary withdrawal of Products from the market); or (ii) by any Authorities to detain or destroy any of the Products. Recall will also include any action by either party to refrain from selling or

 

23

 

shipping quantities of the Products to third parties which would have been subject to a Recall if sold or shipped.

 

(b)                                 Recalls.  If (i) any Authority issues a directive, order or, following the issuance of a safety warning or alert about a Product, a written request that any Product be Recalled, (ii) a court of competent jurisdiction orders a Recall, or (iii) Client determines that any Product should be Recalled or that a “Dear Doctor” letter is required relating the restrictions on the use of any Product, Patheon will co-operate as reasonably required by Client, having regard to all Applicable Laws.

 

(c)                                  Product Returns.  Client will have the responsibility for handling customer returns of the Products.  Patheon will give Client any assistance that Client may reasonably require to handle the returns.

 

6.3                                                                               Patheon’s Responsibility for Defective and Recalled Products.

 

(a)                                 Defective Product.  If Client rejects Products under Section 6.1 and the deviation is determined to have arisen from Patheon’s failure to provide the Manufacturing Services or Products in accordance with the Specifications, cGMPs, Applicable Laws, or other warranties or requirements set forth herein, Patheon will credit Client’s account for Patheon’s invoice price for the defective Products.  If Client previously paid for the defective Products, Patheon will promptly, at Clients election:  (i) refund the invoice price for the defective Products; (ii) offset the amount paid against other amounts due to Patheon hereunder; or (iii) replace the Products with conforming Products without Client being liable for payment therefor, contingent upon Patheon’s receipt from Client of all Active Materials required for the manufacture of the replacement Products.  Patheon’s responsibility for any loss of Active Materials in defective Product will be captured and calculated in the Active Materials Yield under Section 2.2.

 

(b)                                 Recalled Product.  If a Recall, return or other corrective action for the Products results from, or arises out of, a failure by Patheon to perform the Manufacturing Services in accordance with the Specifications, cGMPs, Applicable Laws, or other warranties or requirements set forth herein, Patheon will (i) be responsible for all documented out-of-pocket expenses (including attorneys’ fees and amounts paid to Authorities) of Client and customers of Client of the Recall, return or other corrective action, and (ii) promptly, at Client’s election:  (A) refund the invoice price for the Products that are subject to the Recall, return or other corrective action; (B) offset the amount paid for the Products that are subject to the Recall, return or other corrective action against other amounts due to Patheon hereunder; or (C) replace the Products that are subject to the Recall, return or other corrective action with conforming Products without Client being liable for payment therefor, contingent upon Patheon’s receipt from Client of all Active Materials required for the manufacture of the replacement Products.  Patheon’s responsibility for any loss of Active Materials in Products that are subject to a Recall, return or other corrective action will be captured and calculated in the Active Materials Yield under Section 2.2.  In all circumstances other than those

 

24

 

addressed in this Section 6.3(b), Recalls, returns, or other corrective actions will be made at Client’s cost and expense.

 

(c)                                  Product Claims.  For clarity, Patheon will not be liable to Client, nor have any responsibility to Client, for any deficiencies in, or other liabilities associated with, any Product manufactured by it (collectively, “Product Claims”) to the extent the Product Claim (i) is caused by deficiencies in the Specifications or Client’s marketing or distribution of the Products, (ii) results from a defect in the Active Materials or Components supplied by Client that (x) is not reasonably discoverable by Patheon using the test methods set forth in the Specifications, and (y) has not resulted from Patheon’s storage or handling of the Active Materials or Components, (iii) is caused by actions of third parties occurring after the Product is shipped by Patheon in accordance with Section 5.4, (iv) is due to packaging design or labelling defects or omissions for which Patheon has no responsibility, (v) is determined, by agreement of the parties, after a full quality investigation by the parties in accordance with cGMP requirements, Applicable Laws, and the applicable Quality Agreement, to be due to any unascertainable reason despite Patheon having performed the Manufacturing Services in accordance with the Specifications, the batch production record, Patheon’s standard operating procedures for manufacturing, cGMPs, Applicable Laws, and the other terms and conditions of this Agreement, or (vi) is due to any breach by Client of its obligations under this Agreement.

 

(d)                                 Notice by Patheon.  Patheon immediately will notify Client if at any time Patheon discovers that any Product delivered hereunder does not conform to the Specifications, cGMPs, Applicable Laws, or other warranties or requirements set forth herein.

 

6.4                                                                               Disposition of Defective or Recalled Products.

 

Client will not dispose of any damaged, defective, returned, or Recalled Products for which it intends to assert a claim against Patheon without Patheon’s prior written authorization to do so.  Any storage of this Product (including at Client’s facilities) will be at Patheon’s cost and expense.  Alternatively, Patheon may instruct Client to return any damaged, defective, returned or Recalled Products to Patheon. Patheon will bear the cost of storage, return and disposition for any damaged, defective, returned or Recalled Products for which it bears responsibility under Section 6.3.  In all other circumstances, Client will bear the cost of disposition, including all applicable fees for Manufacturing Services, for any damaged, defective, returned, or Recalled Products.

 

6.5                                                                               Healthcare Provider or Patient Questions and Complaints.

 

Client will have the sole responsibility for responding to questions and complaints from its customers, healthcare providers, and patients.  Questions or complaints received by Patheon from Client’s customers, healthcare providers or patients will be promptly referred to Client in accordance with the terms of the applicable Quality Agreement.  Patheon will co-operate as reasonably required to allow Client to determine the cause of and resolve any

 

25

 

questions and complaints.  This assistance will include follow-up investigations, including testing.  In addition, Patheon will give Client all agreed upon information to enable Client to respond properly to questions or complaints about the Products as set forth in the applicable Quality Agreement.  Unless it is determined that the cause of the complaint resulted from a failure by Patheon to provide the Manufacturing Services and Products in accordance with the Specifications, cGMPs, Applicable Laws or other warranties or requirements set forth herein, all costs incurred under this Section 6.5 will be borne by Client.

 

6.6                                                                               Remedies.

 

Client’s exercise of its rights and remedies under this Article 6 shall not limit its exercise of other rights or remedies to which Client is entitled by the terms of this Agreement.

 

ARTICLE 7
 CO-OPERATION

 

7.1                                                                               Quarterly Review.

 

Each party will forthwith upon execution of this Agreement appoint one of its employees to be a relationship manager responsible for liaison between the parties. The relationship managers will meet not less than quarterly to review the current status of the business relationship and manage any issues that have arisen.

 

7.2                                                                               Authorities.

 

Subject to Section 7.8, each party may communicate with any Authority with regard to the activities described in this Agreement, including but not limited to Regulatory Authorities responsible for granting regulatory approval for the Products, if, in the opinion of that party’s counsel, the communication is necessary to comply with the terms of this Agreement or the requirements of any Applicable Laws.  Unless, in the reasonable opinion of its counsel, there is a legal prohibition against doing so, a party will (a) notify the other party of its intention to make such communications prior to making them to any Authority, (b) permit the other party to accompany and take part in any relevant communications with the Authority, (c) provide the other party with the contents of the proposed communication on a schedule designed to afford the receiving party an opportunity to review and comment thereon, and (d) provide the other party with copies of all communications with the Authority.

 

7.3                                                                               Records and Accounting by Patheon.

 

(a)                                 Patheon will generate, retain and maintain:

 

(i)                                     all records necessary to comply with cGMPs and all other Applicable Laws relating to the manufacture of the Products or any component or intermediate thereof.  Without limiting the foregoing, records will be made concurrently with the performance of each step in the manufacture of Products and in such a manner that at any time successive steps in the manufacture and distribution of any batch may be traced by an inspector.  These records will be legible and indelible, will identify the person

 

26

 

immediately responsible, will include dates of the various steps and be as detailed as necessary for a clear understanding of each step by an individual experienced in the manufacture of pharmaceutical products;

 

(ii)                                  all manufacturing records, standard operating procedures, equipment log books, batch manufacturing records, laboratory notebooks and all raw data relating to the manufacturing of Products and any component or intermediate thereof;

 

(iii)                               samples of each batch of Product and of Active Materials and Components.  Samples will include a quantity of representative material of each batch, Active Materials and Components sufficient to perform at least full duplicate quality control testing, and will specify the dates of manufacture and packaging thereof.  Samples so retained will be selected at random from either final container material or from bulk and final containers; provided that they include at least one final container as a final package, or package-equivalent of such filling of each batch.  Each sample will be stored at temperatures and under conditions which will maintain the identity and integrity of the relevant sample; and

 

(iv)                              such other records and samples as Client reasonably may require in order to ensure compliance by Patheon with the terms of this Agreement and Applicable Laws.

 

(b)                                 Patheon will diligently complete the master batch record for each Product during the manufacture of such Product.

 

(c)                                  Copies of the records and samples will be retained for one year following the date of Product expiry, or longer if required by Applicable Laws, at which time Client will be contacted concerning the delivery to Client or the destruction of the documents and/or samples of Products.  Patheon will not destroy any samples or records without Client’s prior written consent.  Without limiting the preceding sentence, following the expiration of Patheon’s obligation to retain samples, Client will be responsible for retaining samples of the Products necessary to comply with the legal/regulatory requirements applicable to Client.

 

7.4                                                                               Inspection.

 

Client may inspect Patheon’s reports and records relating to this Agreement and Product Agreements during normal business hours and with reasonable advance notice, provided that a Patheon representative must be present during the inspection,

 

7.5                                                                               Access.

 

Patheon will give Client reasonable access at agreed times to the areas of the Manufacturing Site in which the Manufacturing Services are performed to permit Client to observe manufacturing of the Product and to verify that the Manufacturing Services are being performed in accordance with the Specifications, cGMPs, Applicable Laws and other warranties

 

27

 

and requirements set forth herein.  With the exception of “for-cause” audits, Client will be limited each Year to one cGMP-type audit and one inventory observation audit, each lasting no more than two days and involving no more than two auditors, which auditors may be Client’s employees or designated agents.  At Client’s request, Patheon will grant additional cGMP-type audits, additional inventory observation audits, additional audit days, or the participation of additional auditors subject to payment to Patheon of a fee of $5,000 for each additional audit day and $1,000 per audit day for each additional auditor.  The right of access set forth in this Section 7.5 will not include a right to access or inspect Patheon’s financial records.

 

7.6                                                                               Notification of Regulatory Inspections.

 

(a)                                 Patheon will notify Client by telephone within 24 hours, and in writing within two Business Days, after learning of any proposed visit to, or inspection of, a Manufacturing Site by any Regulatory Authority, and immediately by telephone after learning of any unannounced visit to, or inspection of, a Manufacturing Site by any Regulatory Authority if the visit or inspection primarily relates to the Manufacturing Site’s compliance with cGMPs or the manufacture of the Product.

 

(b)                                 In the case of any visit or inspection that relates to the Manufacturing Site’s compliance with cGMPs in respect of the manufacture of the Product or directly to the manufacture of the Product, Patheon will permit Client or its agents to be present at the Manufacturing Site during the visit or inspection.

 

(c)                                  Patheon will provide to Client a copy of (i) any report and other written communication (or the relevant portions thereof) received from a Regulatory Authority in connection with a visit to or inspection of the Manufacturing Site that relates to compliance with cGMPs in respect of the manufacture of the Product or directly to the manufacture of the Product; (ii) any warning letters or similar communications from a Regulatory Authority in respect of the Manufacturing Site; and (iii) any written communications received from a Regulatory Authority relating to the Manufacturing Site’s compliance with cGMPs in respect of the manufacture of the Product or directly to the manufacture of the Product or any component or intermediate thereof or any equipment or manufacturing process used in connection with the manufacture of Product or any component or intermediate thereof, in each case within three Business Days after receipt thereof.  Patheon will consult with Client concerning the response of Patheon to each such communication.  Patheon will provide Client with a copy of all draft responses for comment as soon as possible and all final responses for review and approval, at least five Business Days prior to submission thereof.

 

7.7                                                                               Reports.

 

Patheon will, at its cost, supply on an annual basis all Product data in its control, including release test results, complaint test results, and all investigations (in manufacturing, testing, and storage), that Client reasonably requires in order to complete any filing under any applicable regulatory regime, including any Annual Report that Client is required to file with the FDA.  At Client’s request, Patheon will provide a copy of the Annual Product Review Report to

 

28

 

Client at no additional cost.  Patheon will also provide any additional reports that Client may reasonably request, but any additional reports requested by Client beyond the scope of cGMPs and customary FDA requirements will be subject to an additional fee to be agreed upon between Patheon and Client.

 

7.8                                                                               Regulatory Filings.  Except as otherwise contemplated by Sections 9.3 and 9.5(b), Client will have the sole responsibility and authority for filing all documents with all Regulatory Authorities and taking any other actions that may be required for the receipt and/or maintenance of Regulatory Authority approval for the commercial manufacture of the Products.  Client will be responsible for ensuring the accuracy of the documents provided to the Regulatory Authorities by Client for the Products, and will ensure through use of the change control process that Patheon is provided with the currently filed, active specifications for Products and the information needed to enable Patheon to comply with the applicable requirements of the Product marketing authorizations.  Patheon will assist Client to obtain Regulatory Authority approval for the commercial manufacture of all Products as quickly as reasonably possible.  Without limiting the foregoing, Patheon will cooperate with any reasonable requests for assistance from Client with respect to obtaining and maintaining any and all regulatory approvals required in connection with the sourcing of Product by Client hereunder and the sale of Product in the Territory, including by:

 

(a)                                 at Client’s cost, making its employees, consultants and other staff available upon reasonable notice during normal business hours to attend meetings with Regulatory Authorities concerning Product or any component or intermediate thereof; and

 

(b)                                 at Patheon’s cost, disclosing and making available to Client, in whatever form Client may reasonably request, all manufacturing and quality control data, CMC data and other information related to Product or any component or intermediate thereof and the manufacturing process therefor as is reasonably necessary or desirable to prepare, file, obtain and maintain any regulatory approval required in connection with the sourcing of Product by Client hereunder and the sale of Product in the Territory.

 

ARTICLE 8
 TERM AND TERMINATION

 

8.1                                                                               Initial Term.

 

This Agreement will become effective as of the Effective Date and will continue until December 31, 2018 (the “Initial Term”).  This Agreement will automatically renew after the Initial Term for successive terms of two Years each if there is a Product Agreement in effect, unless either party gives written notice to the other party of its intention to terminate this Agreement at least 18 months prior to the end of the then current term (the Initial Term, together with any renewal periods, the “Term”).  In any event, this Agreement will continue to govern any Product Agreement in effect as provided in Section 1.2.  Each Product Agreement will have an initial term of five Years from the effective date of the Product Agreement unless the parties agree to a different initial term in the applicable Product Agreement (each, an “Initial Product

 

29

 

Term”).  Unless otherwise agreed in the applicable Product Agreement, Product Agreements will automatically renew after the Initial Product Term for successive terms of two Years each unless either party gives written notice to the other party of its intention to terminate the Product Agreement at least (a) 18 months, where Patheon is the party giving such notice or (b) 12 months, where Client is the party giving such notice, prior to the end of the then current term (the Initial Product Term, together with any renewal periods, the “Product Term”).  Notwithstanding the foregoing, this Agreement and any Product Agreement may be terminated in accordance with the provisions of Section 8.2.

 

8.2                                                                               Termination for Cause.

 

(a)                                 Either party at its sole option may terminate this Agreement or a Product Agreement upon written notice where the other party has failed to remedy a material breach of any of its representations, warranties, or other obligations under this Agreement or the Product Agreement within 60 days following receipt of a written notice (the “Remediation Period”) of the breach from the aggrieved party that expressly states that it Is a notice under this Section 8.2(a) (a “Breach Notice”).  The aggrieved party’s right to terminate this Agreement or a Product Agreement under this Section 8.2(a) may only be exercised for a period of 60 days following the expiry of the Remediation Period (where the breach has not been remedied) and if the termination right is not exercised during this period then the aggrieved party will be deemed to have waived the breach of the representation, warranty, or obligation in the instance described in the Breach Notice.

 

(b)                                 Either party may terminate this Agreement immediately upon notice to the other party if the other party (i) files in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction a petition in bankruptcy or insolvency or for reorganization or for arrangement or for the appointment of a receiver or trustee of that party or its assets; (ii) proposes a written agreement of composition or extension of its debts; (iii) is served with an involuntary petition against it, filed in any insolvency proceeding, and this petition is not be dismissed within 60 days after the filing thereof; (iv) becomes a party to any dissolution or liquidation; (v) makes an assignment for the benefit of its creditors; or (vi) admits in writing its inability generally to pay its debts as they become due in the general course.

 

(c)                                  Client may terminate a Product Agreement immediately if any Authority takes any action, or raises any objection, that prevents Client from importing, exporting, purchasing, or selling the Product or Client withdraws the relevant Product from the market as a result of a safety or efficacy issue; provided that Client will still be required to fulfill all of its obligations under Section 8.4 below.

 

(d)                                 Patheon may terminate this Agreement or a Product Agreement upon six months’ prior written notice if Client assigns under Section 13.6 any of its rights under this Agreement or a Product Agreement to an assignee that, in the opinion of Patheon

 

30

 

acting reasonably, is:  (i) not a creditworthy substitute for Client; or (ii) a Patheon Competitor.

 

8.3                                                                               Product Discontinuation.

 

Except if a Product is withdrawn for the reasons specified in Section 8.2(c) or by Client due to safety or efficacy concerns, Client will give at least six months’ advance notice if it intends to no longer order Manufacturing Services for a Product due to this Product’s discontinuance in the market.

 

8.4                                                                               Obligations on Termination.

 

If this Agreement is terminated for any reason, then:

 

(a)                                 Client will take delivery of and pay for all undelivered Products that have been manufactured and/or packaged under a Firm Order, at the price in effect at the time the Firm Order was placed;

 

(b)                                 Client will purchase, at Patheon’s cost (including all costs incurred by Patheon for the purchase and handling of the Inventory), the Inventory that was purchased, produced or maintained by Patheon for use in then-current Firm Orders and prior to the notice of termination being given;

 

(c)                                  Client acknowledges that Patheon will not be required to permit a Patheon Competitor to access the Manufacturing Site; and

 

(d)                                 Client will make commercially reasonable efforts, at its own expense, to remove from the Manufacturing Site, within 30 days, all unused Active Material, all applicable inventory and Materials (whether current or obsolete), supplies, undelivered Product, chattels, equipment or other moveable property owned by Client, related to the Product Agreement and located at a Manufacturing Site or that is otherwise under Patheon’s care and control (“Client Property”).  If Client fails to remove the Client Property within 30 days following written notice from Patheon describing the nature and location of all Client Property to be removed by Client due to the completion, termination or expiration of a Product Agreement, Client will pay Patheon $[***] per pallet, per month, one pallet minimum (except that Client will pay $[***] per pallet, per month, one pallet minimum, for any of the Client Property that contains controlled substances, requires refrigeration or other special storage requirements) thereafter for storing the Client Property and will assume any reasonable third party storage charges invoiced to Patheon regarding the Client Property.  Patheon will invoice Client for the storage charges as set forth in Section 5.5 of this Agreement.

 

Any termination of this Agreement or a Product Agreement will not affect any outstanding obligations or payments due that have arisen prior to the termination, nor will it prejudice any other remedies that the parties may have under this Agreement or a Product Agreement.  The provisions of Articles 6, 7, 9, 10, 11 and

 

*** Confidential Treatment Requested

 

31

 

12, and Sections 2.2, 4.6, 5.4, 5.5, 13.1, 13.2, 13.3, 13.9, 13.19, 13.20 and this Section 8.4, will survive termination of this Agreement.

 

ARTICLE 9
 REPRESENTATIONS, WARRANTIES AND COVENANTS

 

9.1                                                                               Authority.

 

Each party hereby represents and warrants to the other party as follows:

 

(a)                                 The party (i) is duly formed and in good standing under the laws of the jurisdiction of its formation, (ii) has the power and authority and the legal right to enter into this Agreement and perform its obligations hereunder, and (iii) has taken all necessary action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder.  This Agreement has been duly executed and delivered by the party and constitutes a legal, valid and binding obligation of the party and is enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other similar laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity, whether enforceability is considered in a proceeding at law or equity.

 

(b)                                 All necessary consents, approvals and authorizations of all Authorities and other persons required to be obtained by such party in connection with (i) the execution and delivery of this Agreement have been obtained and (ii) the performance of its obligations hereunder have been obtained or will be obtained prior to the time that these consents, approvals and authorizations are required.

 

(c)                                  The execution and delivery of this Agreement and the performance of the party’s obligations hereunder (i) do not and will not conflict with or violate any requirement of Applicable Laws or any provision of the articles of Incorporation, bylaws or any other constitutive document of such party and (ii) do not and will not conflict with, violate, or breach, or constitute a default or require any consent under, any contractual obligation or court or administrative order by which the party is bound.

 

9.2                                                                               Client Representations, Warranties, and Covenants.

 

Client covenants, represents, and warrants that:

 

(a)                                 Non-infringement.

 

(i)                                   the Specifications for each of the Products do not infringe any Third Party Rights and Client may lawfully disclose the Specifications to Patheon;

 

32

 

(ii)                                any Client Intellectual Property used by Patheon in performing the Manufacturing Services according to the Specifications may be lawfully used as directed by Client without infringing any Third Party Rights; and

 

(iii)                             to Client’s knowledge, there are no pending legal proceedings claiming that any of the Specifications, or any of the Active Materials and the Components, or the sale, use, or other disposition of any Product made in accordance with the Specifications infringes any Third Party Rights.

 

(b)                                 Quality and Compliance.

 

(i)                                   the Specifications for a Product will be consistent with the specifications set forth in the Product’s applicable marketing authorization;

 

(ii)                                the Products, if labelled and manufactured in accordance with the Specifications and in compliance with applicable cGMPs and Applicable Laws, may be lawfully sold and distributed in every jurisdiction in which Client will sell and distribute the Products; and

 

(iii)                             on the date of shipment by or on behalf of Client to Patheon, the Active Materials will conform to the Specifications for the Active Materials that Client has given to Patheon and the Active Materials will be adequately contained, packaged, and labelled and will conform to the affirmations of fact on the container.

 

9.3                                                                               Patheon Representations, Warranties, and Covenants.

 

Patheon covenants, represents, and warrants that:

 

(a)                                 it will perform the Manufacturing Services and provide Products to Client in accordance with the Specifications, cGMPs, Applicable Laws and any other warranties or other requirements herein;

 

(b)                                 At the time of delivery of Product by Patheon, with regard to the Product:

 

(i)                                   the Manufacturing Site at which the Product was manufactured, at the time of manufacture, was in compliance with all cGMPs and other Applicable Laws (including applicable inspection requirements of the FDA);

 

(ii)                                the Product will have been manufactured in strict compliance with the requirements of cGMPs, this Agreement, the Quality Agreement, the Specifications and all Applicable Laws;

 

(iii)                             the Product will be in conformity with the Specifications;

 

(iv)                            the Product will have a remaining shelf life of at least 80% of the Product’s approved shelf life from the date of manufacture;

 

33

 

(v)                                 title to the Product will pass to Client free and clear of any security interest, lien or other encumbrance;

 

(vi)                              the Product will not be adulterated or misbranded under the Federal Food, Drug, and Cosmetic Act (“FFDCA”); and

 

(vii)                           no act or omission of Patheon would cause or result in the Product being a product that cannot be introduced into interstate commerce pursuant to the FFDCA.

 

(c)                                  any Intellectual Property used by Patheon to perform the Manufacturing Services (other than Intellectual Property provided by Client) may be lawfully used by Patheon without infringing any Third Party Rights.

 

9.4                                                                               Debarred Persons.

 

Patheon hereby represents, warrants, and covenants to Client that (a) neither Patheon nor any of its Affiliates has been debarred or is subject to debarment pursuant to Section 306 of the FFDCA or any similar law in any country in the Territory or listed on either Excluded List, and (b) neither Patheon nor any of its Affiliates will use in any capacity, including as officer, director, managing employee, or any other way, in connection with the services to be performed under this Agreement, any person who has been debarred pursuant to Section 306 of the FFDCA or any similar law in any country in the Territory, or who is the subject of a conviction described in such section or listed on either Excluded List. Patheon will inform Client in writing immediately if it or any person who is performing services hereunder is debarred or is the subject of a conviction described in Section 306 of the FFDCA or any similar law in any country in the Territory or listed on either Excluded List, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to the best of Patheon’s knowledge, is threatened, relating to the debarment or conviction Section 306 of the FFDCA or any similar law in any country in the Territory, or listing on either Excluded List, of Patheon or any person performing services hereunder.

 

9.5                                                                               Permits.

 

(a)                                 Client will be solely responsible for obtaining or maintaining, on a timely basis, any permits or other regulatory approvals for the marketing and sale of the Products, including, without limitation, all marketing and post-marketing approvals.

 

(b)                                 Patheon represents, warrants and covenants to Client that it has obtained, or will obtain prior to the time that Governmental Approval is required, and will maintain in full force and effect and in good standing, any and all Governmental Approvals required by Applicable Laws to be held by Patheon in order to provide the Manufacturing Services for the Products at its Manufacturing Sites and to perform all of its other obligations hereunder in accordance with the terms of this Agreement and the Product Agreements.

 

34

 

9.6                                                                               No Warranty.

 

EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

 

ARTICLE 10
 REMEDIES AND INDEMNITIES

 

10.1                                                                        Consequential Damages.

 

Except for breaches of Article 11, neither party will be liable to the other in contract, tort, negligence, breach of statutory duty, or otherwise for any loss of profits, of production, of anticipated savings, of business, or goodwill or for any other liability, damage, costs, or expense of any kind incurred by the other party of an indirect or consequential nature, regardless of any notice of the possibility of these damages.  This disclaimer does not extend to damages owed to third parties pursuant to Sections 10.3 or 10.4.

 

10.2                                                                        Limitation of Liability.

 

(a)                                 Active Materials.  Except for loss and damage for which provision is made in Section 2.2, under no circumstances will Patheon be responsible for any loss or damage to the Active Materials. Patheon’s maximum responsibility for loss or damage to the Active Materials with respect to a Product in a given Year will not exceed the Maximum Credit Value set forth in Schedule D of the applicable Product Agreement.

 

(b)                                 Maximum Liability.  Patheon’s maximum aggregate liability to Client under this Agreement or any Product Agreement in any Year for any reason whatsoever, including, without limitation, any liability arising from any and all breaches of its representations, warranties, or any other obligations under this Agreement or any Product Agreement, will not exceed, on a per Product basis, the “Maximum Amount” specified in the applicable Product Agreement.  Notwithstanding the foregoing, the parties agree that the limitation on liability described in this Section 10.2(b) will not apply to, nor take into account, any Patheon liability arising under Section 10.3 or Article 11 or from [***].

 

10.3                                                                        Indemnification by Patheon.

 

Patheon will indemnify Client, its Affiliates and its and their respective directors, officers, employees and agents (the “Client Indemnitees”), and defend and hold each of them harmless from and against any and all losses, damages, liabilities, penalties, costs and expenses (including reasonable attorneys’ fees and disbursements) (collectively, “Losses”) arising from or occurring as a result of (a) any third party claims, lawsuits, actions or proceedings (“Third Party

 

*** Confidential Treatment Requested

 

35

 

Claims”) against a Client Indemnitee arising from or occurring as a result of (i) the breach by Patheon of this Agreement; (ii) the negligence or willful misconduct of any Patheon Indemnitee in connection with the performance of this Agreement; (iii) any claim that the use or practice of Patheon Intellectual Property in connection with the manufacture of any Product violates, breaches, or infringes any Third Party Rights, or (iv) the handling, release, or disposal of any waste by Patheon; (b) any personal injury or death suffered by any Patheon Indemnitee in connection with the manufacturing of Product hereunder or the performance of Patheon’s other obligations hereunder; or (c) the enforcement by a Client Indemnitee of its rights under this Section 10.3; except in each case for those Losses for which Client has an obligation to indemnify the Patheon Indemnitees pursuant to Section 10.4, as to which Losses each party will indemnify the other party to the extent of its respective liability for such Losses.

 

10.4                                                                        Indemnification by Client.

 

Client will indemnify Patheon, its Affiliates and its and their respective directors, officers, employees and agents (collectively, the “Patheon Indemnitees”) and defend and hold each of them harmless from and against any and all Losses arising from or occurring as a result of (a) any Third Party Claims against a Patheon Indemnitee arising from or occurring as a result of (i) the breach by Client of this Agreement; (ii) the negligence or willful misconduct of any Client Indemnitee in connection with the performance of this Agreement; or (iii) any claim that the use of Active Materials or the use or practice of Client Intellectual Property in connection with the manufacture of any Product in accordance with the terms of this Agreement violates, breaches, or infringes any Third Party Rights; and (b) the enforcement by a Patheon Indemnitee of its rights under this Section 10.4; except in each case for those Losses for which Patheon has an obligation to indemnify the Client Indemnitees pursuant to Section 10.3, as to which Losses each party will indemnify the other party to the extent of Its respective liability for such Losses.

 

10.5                                                                        Indemnification Procedure.

 

(a)                                 Notice.  The indemnified party (the “Indemnified Party”) will promptly provide the indemnifying party (the “Indemnifying Party”) notice (“Indemnification Claim Notice”) of any Loss or discovery of fact upon which such Indemnified Party intends to base a request for indemnification under Section 10.3 or 10.4, but any delay in providing such notice will qualify the obligations of the Indemnifying Party under Section 10.3 or 10.4, as relevant, only to the extent of actual prejudice to the ability of the Indemnifying Party to defend the claim. Each Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss are known at such time).

 

(b)                                 Third Party Claims.  The obligations of an Indemnifying Party under this Article 10 with respect to Third Party Claims will be governed by and be contingent upon the following:

 

(i)                                     Defense.  At its option, the Indemnifying Party may assume the defense of any Third Party Claim by giving notice to the indemnified Party within 30 days after the Indemnifying Party’s receipt of an Indemnification Claim

 

36

 

Notice; provided that the assumption of the defense of a Third Party Claim by the Indemnifying Party will constitute an acknowledgment that the Indemnifying Party is liable to indemnify hereunder the Indemnified Party in respect of such Third Party Claim.  Upon assuming the defense of a Third Party Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel selected by the Indemnifying Party which will be reasonably acceptable to the Indemnified Party.  If the Indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party will immediately deliver to the Indemnifying Party all original notices and documents (including court papers) received by the Indemnified Party in connection with the Third Party Claim.  Subject to Section 10.5(b)(ii), if the Indemnifying Party assumes the defense of a Third Party Claim, the Indemnifying Party will not be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense or settlement of the Third Party Claim.

 

(ii)                                  Right to Participate in Defense.  Without limiting Section 10.5(b)(i), any Indemnified Party will be entitled to participate in, but not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided, however, that such employment will be at the Indemnified Party’s own expense unless

 

(A)                               the employment thereof, and the assumption by the Indemnifying Party of such expense, has been specifically authorized by the Indemnifying Party in writing;

 

(B)                               the Indemnifying Party has failed to assume the defense and employ counsel in accordance with Section 10.5(b)(i) (in which case the Indemnified Party will control the defense); or

 

(C)                               the interests of the Indemnified Party and the Indemnifying Party with respect to such Third Party Claim are sufficiently adverse to make inappropriate or impermissible the representation by the same counsel of both parties under Applicable Laws, ethical rules or equitable principles.

 

(iii)                               Settlement.  With respect to any Losses relating solely to the payment of money damages in connection with a Third Party Claim and that will not constitute an admission of liability by the Indemnified Party, result in the Indemnified Party’s becoming subject to injunctive or other relief or otherwise adversely affect the business of the Indemnified Party in any manner, and as to which the Indemnifying Party will have acknowledged in writing the obligation to indemnify the Indemnified Party hereunder, the Indemnifying Party will have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the Indemnifying Party, in its sole discretion, will deem appropriate.  With respect to all other Losses in connection with Third Party Claims, where the Indemnifying Party has assumed the defense of

 

37

 

the Third Party Claim in accordance with Section 10.5(b)(1), the Indemnifying Party will have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss; provided that it obtains the prior written consent of the Indemnified Party (which consent will not be unreasonably withheld, conditioned or delayed).  The Indemnifying Party will not be liable for any settlement or other disposition of a Loss by an Indemnified Party that is reached without the written consent of the Indemnifying Party.  Regardless of whether the Indemnifying Party chooses to defend any Third Party Claim, no Indemnified Party will admit any liability with respect to, or settle, compromise or dispose of, any Third Party Claim for which it intends to seek indemnification pursuant to Section 10.3 or 10.4, as applicable, without the prior written consent of the Indemnifying Party (which consent will not be unreasonably withheld, conditioned or delayed).

 

(iv)                              Cooperation.  If the Indemnifying Party chooses to defend any Third Party Claim, the Indemnified Party will cooperate in the defense thereof and will furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith.  Such cooperation will include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim, and making employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder.  The Indemnifying Party will reimburse the Indemnified Party for all its reasonable out-of-pocket expenses in connection with the foregoing.

 

(v)                                 Expenses.  Except as provided above, the reasonable and verifiable out-of-pocket costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with any Third Party Claim will be reimbursed on a monthly basis in arrears by the Indemnifying Party.

 

10.6                                                                        Reasonable Allocation of Risk.

 

The parties acknowledge and agree that this Agreement (including, without limitation, this Article 10) is reasonable and creates a reasonable allocation of risk for the relative profits the parties each expect to derive from the Products.

 

ARTICLE 11
 CONFIDENTIALITY

 

11.1                                                                        Confidentiality Agreement.  This Agreement replaces and supersedes the Confidentiality Agreement in its entirety, and any Disclosed Information to which the terms of the Confidentiality Agreement apply as of the Effective Date will be deemed to be Confidential

 

38

 

Information for purposes of this Agreement and will be subject to the terms set forth in this Article 11.

 

11.2                                                                        Confidential Information.  Subject to the provisions of Sections 11,3 and 11.4, at all times during the Term and for seven years following the termination of this Agreement, the party receiving Confidential Information (the “Receiving Party”) (a) will keep completely confidential and will not publish or otherwise disclose any Confidential Information furnished to it by the other party (the “Disclosing Party”), except to those of the Receiving Party’s employees, Affiliates, or consultants who have a need to know such information to perform such party’s obligations hereunder (and who will be advised of the Receiving Party’s obligations hereunder and who are bound by confidentiality obligations with respect to such Confidential Information no less onerous than those set forth in this Agreement) (collectively, “Recipients”) and (b) will not use Confidential Information of the Disclosing Party directly or indirectly for any purpose other than performing its obligations or exercising its rights hereunder.  The Receiving Party will be jointly and severally liable for any breach by any of its Recipients of the restrictions set forth in this Agreement.  Notwithstanding the foregoing, Client will be deemed to be the Disclosing Party, and Patheon the Receiving Party, with respect to any Confidential Information that is included in the Client Intellectual Property.

 

11.3                                                                        Exceptions to Confidentiality.  The Receiving Party’s obligations set forth in this Agreement will not extend to any Confidential Information of the Disclosing Party:

 

(a)                                 that is or hereafter becomes part of the public domain by public use, publication, general knowledge or the like through no wrongful act, fault or negligence on the part of a Receiving Party or its Recipients;

 

(b)                                 that is received by the Receiving Party from a third party without restriction and without breach of any obligation of confidentiality to which such third party is subject;

 

(c)                                  that the Receiving Party can demonstrate by competent evidence was already in its possession without any limitation on use or disclosure prior to its receipt from the Disclosing Party;

 

(d)                                 that is generally made available to third parties by the Disclosing Party without restriction on disclosure; or

 

(e)                                  that the Receiving Party can demonstrate by competent evidence was independently developed by the Receiving Party.

 

11.4                                                                        Disclosure.

 

(a)                                 Each party may disclose Confidential information to the extent that such disclosure is:

 

(i)                                     made in response to a valid order of a court of competent jurisdiction or other governmental body of a country or any political subdivision thereof of competent jurisdiction; provided, however, that, if permitted by

 

39

 

Applicable Laws, the Receiving Party will first have given notice to the Disclosing Party and given the Disclosing Party a reasonable opportunity to quash such order or to obtain a protective order requiring that the Confidential Information or documents that are the subject of such order be held in confidence by such court or governmental body or, if disclosed, be used only for the purposes for which the order was issued; and provided further that if a disclosure order is not quashed or a protective order is not obtained, the Confidential Information disclosed in response to such court or governmental order will be limited to that information that is legally required to be disclosed in response to such court or governmental order;

 

(ii)                                  otherwise required by Applicable Laws, in the opinion of legal counsel to the Receiving Party; provided, however, that reasonable measures will be taken to assure confidential treatment of such information.

 

(b)                                 Client may disclose Confidential Information to the extent that such disclosure is made to Regulatory Authorities as required in connection with any filing or application; provided, however, that reasonable measures will be taken to assure confidential treatment of such information.

 

(c)                                  Unless and until Client provides Patheon with written notice to the contrary, Patheon may (i) use Confidential Information as to which Client is the Disclosing Party solely to the extent necessary to manufacture and supply Crofelemer Product for Glenmark Pharma, and (ii) disclose Confidential Information as to which Client is the Disclosing Party to Glenmark Pharma solely in connection with such manufacturing and supply of Crofelemer Product, provided that Glenmark Pharma is advised of Patheon’s obligations under this Article 11 and is bound by confidentiality obligations to Patheon no less onerous than those set forth herein.

 

40

 

11.5                                                                        Notification.  The Receiving Party will notify the Disclosing Party immediately, and cooperate with the Disclosing Party as the Disclosing Party may reasonably request, upon the Receiving Party’s discovery of any loss or compromise of the Disclosing Party’s Confidential Information.

 

11.6                                                                        Remedies.  Each party agrees that the unauthorized use or disclosure of any information by the Receiving Party in violation of this Agreement will cause severe and irreparable damage to the Disclosing Party.  In the event of any violation of this Article 11, the Receiving Party agrees that the Disclosing Party will be authorized and entitled to obtain from any court of competent jurisdiction injunctive relief, whether preliminary or permanent, without the necessity of proving irreparable harm or monetary damages, as well as any other relief permitted by Applicable Laws.  The Receiving Party agrees to waive any requirement that the Disclosing Party post bond as a condition for obtaining any such relief.

 

ARTICLE 12
 DISPUTE RESOLUTION

 

12.1                                                                        Dispute Resolution.  Any dispute, controversy or claim arising out of or relating to this Agreement or the breach, termination or validity thereof (each, a “Dispute”), will be referred to a senior executive of each party.  The senior executives will meet to attempt to resolve the Dispute by good faith negotiations within 30 days of referral of the Dispute.  If the Dispute remains unresolved after this 30-day negotiation period, then, at the election of either party, the Dispute will be decided in accordance with Section 13.20.

 

ARTICLE 13
 MISCELLANEOUS

 

13.1                                                                        Intellectual Property Ownership and Licenses.

 

(a)                                 License Grants to Patheon.

 

(i)                                     For the term of this Agreement, Client hereby grants to Patheon a non-exclusive, paid-up, royalty-free, non-transferable license, solely for purposes of Patheon’s performing the Manufacturing Services, of Client Intellectual Property, and all other Intellectual Property as to which Client may grant such a license, that Patheon must use in order to perform the Manufacturing Services.

 

(ii)                                  Client hereby grants to Patheon a perpetual, non-exclusive, paid-up, royalty-free, transferable license, solely to enable Patheon to manufacture or develop products for any of its third-party clients, of any intellectual Property included in the Product IP that has general application to manufacturing processes, the formulation or development of drug products, drug product dosage forms or drug delivery systems and is not specific to any Product or Active Materials.

 

(b)                                 License Grant to Client.  Patheon hereby grants to Client a perpetual, irrevocable, non-exclusive, paid-up, royalty-free, transferable license to use the Patheon

 

41

 

intellectual Property and any Information used by Patheon to perform the Manufacturing Services to enable Client to manufacture, develop, commercialize, market and sell the Product(s).

 

(c)                                  Ownership of Intellectual Property.

 

(i)                                     Client Intellectual Property will be the exclusive property of Client.  Patheon will, and will cause its Affiliates to, promptly disclose in writing to Salix the discovery, development, making, conception, or reduction to practice of any Invention included in or giving rise to Client Intellectual Property and, upon Client’s request, execute all instruments and other documents that are required to vest ownership in Client.

 

(ii)                                  Patheon Intellectual Property will be the exclusive property of Patheon.

 

(iii)                               Except as otherwise provided in Section 13.1(d)(iii) for Joint Invention Patents, each party will be solely responsible for the costs of filing, prosecution, and maintenance of patents and patent applications included in or claiming Intellectual Property as to which it is allocated ownership hereunder.

 

(d)                                 Joint Intellectual Property.

 

(i)                                     The parties will jointly own all right, title and interest in and to Joint Intellectual Property.  Each party will, and will cause its Affiliates to, promptly disclose in writing to the other party the discovery, development, making, conception or reduction to practice of any Invention included in or giving rise to Joint Intellectual Property.

 

(ii)                                  Patheon will, and does hereby, grant to Client an irrevocable, perpetual, fully paid-up, royalty-free, non-exclusive license, with the right to grant sublicenses through multiple tiers, to use for any purpose all of Patheon’s right, title and interest in and to all Joint Intellectual Property. Client will, and does hereby, grant to Patheon an irrevocable, perpetual, fully paid-up, royalty-free, non-exclusive license, with the right to grant sublicenses through multiple tiers, to use for any purpose all of Client’s right, title and interest in and to all Joint Intellectual Property.

 

(iii)                               Client will have the first right, but not the obligation, to prepare, file, prosecute, and maintain any patent applications and patents included in or giving rise to Joint Intellectual Property (the “Joint Invention Patents”) and will be responsible for related interference, re-issuance, re-examination and opposition proceedings.  But if Client plans to abandon any Joint Invention Patent, then Client will notify Patheon in writing at least 90 days in advance of the due date of any payment or other action that is required to prepare, file, prosecute or maintain such Joint Invention Patent, and Patheon may elect, upon written notice within such 90 day

 

42

 

period to Client, to make such payment or take such action, at its own expense.

 

13.2                                                                        No Implied Rights.

 

Except as provided in Section 13.1, neither party has, nor will it acquire, any interest in any of the other party’s Intellectual Property unless otherwise expressly agreed to In writing. Neither party will use any Intellectual Property of the other party except as specifically authorized herein or in writing by the other party.

 

13.3                                                                        Insurance.

 

(a)                                 Subject to Section 13.3(b), each party will maintain commercial general liability insurance, including blanket contractual liability insurance covering the obligations of that party under this Agreement, through the term of this Agreement and for a period of three years thereafter.  This insurance will have policy limits of not less than (i) $5,000,000 for each occurrence for personal injury or property damage liability, and (ii) $5,000,000 in the aggregate per annum for product and completed operations liability.  If requested, each party will give the other a certificate of insurance evidencing the above and showing the name of the issuing company, the policy number, the effective date, the expiration date, and the limits of liability.  The insurance certificate will further provide for a minimum of 30 days’ written notice to the insured of a cancellation of, or material change in, the insurance.

 

(b)                                 If a party is unable to maintain the insurance policies required under this Agreement on commercially reasonable terms and at commercially reasonable cost through no fault of its own, then the party will forthwith notify the other party in writing and the parties will in good faith negotiate appropriate amendments to the insurance provision of this Agreement in order to provide adequate assurances on commercially reasonable terms and at commercially reasonable cost.

 

13.4                                                                        Independent Contractors.

 

The parties are independent contractors and this Agreement and any Product Agreement will not be construed to create between Patheon and Client any other relationship, such as, by way of example only, that of employer-employee, principal-agent, joint-venturer, co-partners, or any similar relationship, the existence of which is expressly denied by the parties.

 

13.5                                                                        No Waiver.

 

Either party’s failure to require the other party to comply with any provision of this Agreement or any Product Agreement will not be deemed a waiver of the provision or any other provision of this Agreement or any Product Agreement, except as expressly set forth in Sections 6.1 and 8.2(a).

 

43

 

13.6                                                                        Assignment.

 

(a)                                 Patheon may not assign this Agreement or any Product Agreement or any of its associated rights or obligations without the written consent of Client.  Patheon will not arrange for any subcontractor to perform testing or other services arising under any Product Agreement without obtaining Client’s prior written consent for the use of the subcontractor, this consent not to be unreasonably withheld.  Further, it is specifically agreed that Patheon may subcontract any part of the Services under a Product Agreement to any of its Affiliates.

 

(b)                                 Subject to Section 8.2(d), Client may assign this Agreement or any Product Agreement or any of its associated rights or obligations without approval from Patheon.  But Client will give Patheon prior written notice of any assignment, and any assignee will be required to agree in writing with Patheon to be bound by the terms of this Agreement or the applicable Product Agreement.  In the event of a partial assignment in which Client assigns one or more (but not all) Product Agreements and this Agreement solely as it relates to such assigned Product Agreement(s) to a third party who is not an Affiliate of Client, then Patheon will have the right to request a re-negotiation of fees paid under the assigned agreement(s) with the assignee and, if good faith discussions do not lead to agreement on amended fees applicable to such assigned agreement(s) within a reasonable time, then on 12 months’ prior written notice to Client and the assignee, Patheon will have the right to terminate the assigned Product Agreement(s).

 

(c)                                  Despite the foregoing provisions of this Section 13.6, either party may assign this Agreement or any Product Agreement to any of its Affiliates or to a successor to or purchaser of all or substantially all of its business, but the assignee must execute an agreement with the non-assigning party whereby it agrees to be bound hereunder.

 

(d)                                 Any purported assignment in breach of the provisions of this Section 13.6 will be void and of no effect.

 

13.7                                                                        Force Majeure.

 

Neither party will be liable for the failure to perform its obligations under this Agreement or any Product Agreement if the failure is caused by an event beyond that party’s reasonable control, including, but not limited to, strikes or other labor disturbances, lockouts, riots, quarantines, communicable disease outbreaks, wars, acts of terrorism, fires, floods, storms, interruption of or delay in transportation, lack of or inability to obtain fuel, power or components, or compliance with any order or regulation of any government entity acting within colour of right (a “Force Majeure Event”).  A party claiming a right to excused performance under this Section 13.7 will immediately notify the other party in writing of the extent of its inability to perform, which notice will specify the event beyond its reasonable control that prevents the performance and steps to be taken by it to remedy the same. The suspension of performance will be of no greater scope and no longer duration than is reasonably required and

 

44

 

the non-performing party will use commercially reasonable efforts to remedy Its inability to perform as soon as possible.  If the suspension of performance continues for 60 days after the date of the occurrence, and the failure to perform would constitute a material breach of this Agreement in the absence of the Force Majeure Event, the nonaffected party may terminate this Agreement immediately by written notice to the affected party.  Neither party will be entitled to rely on a Force Majeure Event to relieve it from an obligation to pay money (including any interest for delayed payment) which would otherwise be due and payable under this Agreement or any Product Agreement.

 

13.8                                                                        Additional Product.

 

Additional Products may be added to, or existing Products deleted from, any Product Agreement by amendments to the Product Agreement including Schedules A, B, C, and D as applicable.

 

13.9                                                                        Notices.

 

(a)                                 Any notice, request, demand, waiver, consent, approval, or other communication permitted or required under this Agreement will be in writing, will refer specifically to this Agreement, and will be deemed given only if delivered by hand or sent by facsimile transmission (with transmission confirmed) or by nationally recognized overnight delivery service that maintains records of delivery, addressed to the parties at their respective addresses specified in Section 13.9(b) or to such other address as the party to whom notice is to be given may have provided to the other party in accordance with this Section 13.9.  Such notice will be deemed to have been given as of the date delivered by hand or transmitted by facsimile (with transmission confirmed) or on the second Business Day (at the place of delivery) after deposit with a nationally recognized overnight delivery service.  Any notice delivered by facsimile will be confirmed by a hard copy delivered as soon as practicable thereafter.  This Section 13.9 is not intended to govern the day-to-day business communications necessary between the parties in performing their obligations under the terms of this Agreement.

 

(b)                                 Address for Notice: if to Client:

 

Salix Pharmaceuticals, Inc.

8610 Colonnade Center Drive

Raleigh, NC 27615

Attention: Chief Financial Officer

Telecopier No.: 919-862-1095

 

with a copy to:

 

Salix Pharmaceuticals, Inc.

8510 Colonnade Center Drive

Raleigh, NC 27615

Attention: General Counsel

Telecopier No.: 919-862-1095

 

45

 

If to Patheon:

 

Patheon Pharmaceuticals Inc

2110 East Galbraith Road

Cincinnati, OH 45237-1625

Attention: Director of Legal Services

Telecopier No.: 513-948-6927

Email address: Frank.McCune@patheon.com

 

With a copy to:

 

Patheon Inc.

4721 Emperor Boulevard

Research Triangle Park,

NC 27703

Attention: General Counsel

Telecopier No.: 919-474-2269

Email address: Michaellytton@patheon.com

 

13.10                                                                 Severabilitv.

 

If any provision of this Agreement or any Product Agreement is determined by a court of competent jurisdiction to be invalid, illegal, or unenforceable in any respect, that determination will not impair or affect the validity, legality, or enforceability of the remaining provisions, because each provision is separate, severable, and distinct.

 

13.11                                                                 Entire Agreement.

 

This Agreement, together with the applicable Product Agreement and Quality Agreement, constitutes the full, complete, final and integrated agreement between the parties relating to the subject matter hereof and supersedes all previous written or oral negotiations, commitments, agreements, transactions, or understandings concerning the subject matter hereof. Any modification, amendment, or supplement to this Agreement or any Product Agreement must be in writing and signed by authorized representatives of both parties. In case of conflict, the prevailing order of documents will be this Agreement, then the Product Agreement and then the Quality Agreement.

 

13.12                                                                 Other Terms,

 

No terms, provisions or conditions of any purchase order or other business form or written authorization used by Client or Patheon will have any effect on the rights, duties, or obligations of the parties under, or otherwise modify, this Agreement or any Product Agreement, regardless of any failure of Client or Patheon to object to the terms, provisions, or conditions, unless the document specifically refers to this Agreement or the applicable Product Agreement and is signed by both parties.

 

46

 

13.13                                                                 No Third Party Benefit or Right.

 

For greater certainty, nothing in this Agreement or any Product Agreement will confer or be construed as conferring on any third party any benefit or the right to enforce any express or implied term of this Agreement or any Product Agreement.

 

13.14                                                                 Execution in Counterparts.

 

This Agreement and any Product Agreement may be executed in two or more counterparts, by original or facsimile or electronically-transmitted signature, each of which will be deemed an original, but all of which together will constitute one and the same instrument.

 

13.15                                                                 Further Assurances.  Each party will duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments as may be necessary or as the other party may reasonably request, in connection with this Agreement or to carry out more effectively the provisions and purposes hereof or to better assure and confirm unto such other party its rights and remedies under this Agreement.

 

13.16                                                                 Export Control.  This Agreement is made subject to any restrictions concerning the export of products or technical information from the United States or other countries that may be imposed on the parties from time to time. Each party agrees that it will not export, directly or indirectly, any technical information acquired from the other party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first obtaining the written consent to do so from the appropriate agency or other governmental entity in accordance with Applicable Laws.

 

13.17                                                                 Waiver.  Any term or condition of this Agreement may be waived at any time by the party that is entitled to the benefit thereof, but no such waiver will be effective unless set forth in a written instrument duly executed by or on behalf of the party waiving such term or condition. No waiver by either party of any term or condition of this Agreement, in any one or more instances, will be deemed to be or construed as a waiver of the same or any other term or condition of this Agreement on any future occasion.

 

13.18                                                                 Construction.  Unless the context of this Agreement otherwise requires: (a) words of any gender include each other gender; (b) words using the singular or plural number also include the plural or singular number, respectively; (c) the term “or” has, except where otherwise indicated, the inclusive meaning represented by the phrase “and/or”; (d) the term “including” or “includes” means “including without limitation” or “includes without limitation”; and, (e) except where otherwise indicated, references to any agreement, instrument or other document in this Agreement refer to such agreement, instrument or other document as originally executed or, if subsequently amended, replaced or supplemented from time to time, as so amended, replaced or supplemented and in effect at the relevant time of reference thereto. Whenever this Agreement refers to a number of days, such number will refer to calendar days unless Business Days are specified. The captions of this Agreement are for convenience of reference only and in no way define, describe, extend, or limit the scope or intent of this

 

47

 

Agreement or the intent of any provision contained in this Agreement. The language of this Agreement will be deemed to be the language mutually chosen by the parties and no rule of strict construction will be applied against any party.

 

13.19                                                                 Use of Client Name.

 

Patheon will not make any use of Client’s name, trademarks or logo or any variations thereof, alone or with any other word or words, without the prior written consent of Client.

 

13.20                                                                 Governing Law; Jurisdiction; Venue; Service.

 

(a)                                 This Agreement and, unless otherwise agreed by the parties, any Product Agreement, will be construed and enforced in accordance with the laws of the State of New York, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The UN Convention on Contracts for the International Sale of Goods will not apply to this Agreement.

 

(b)                                 Subject to Section 12.1, each party irrevocably and unconditionally consents to the exclusive jurisdiction of the courts of general jurisdiction of the State of New York and the United States District Court for the Southern District of New York sitting in the Borough of Manhattan (collectively, the “Courts”) for any action, suit or proceeding (other than appeals therefrom) concerning any matter arising out of or relating to this Agreement, and agrees not to commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such Courts.

 

(c)                                  Each party hereto further hereby irrevocably and unconditionally waives any objection to the laying of venue of any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement in the Courts and hereby further irrevocably and unconditionally agrees not to raise any objection at any time to the laying or maintaining of the venue of any such action, suit or proceeding in any of such Courts, irrevocably waives any claim that such action, suit or other proceeding has been brought in an inconvenient forum and further irrevocably waives the right to object, with respect to such action, suit or other proceeding, that such Court does not have any jurisdiction over such party.

 

(d)                                 Each party hereto further agrees that, to the maximum extent permitted by Applicable Laws, service of any process, summons, notice or document by United States registered mail to its address and contact person for notices provided for in Section 13.9 will be effective service of process for any action, suit or proceeding brought against it under this Agreement in any of the Courts.

 

[Signature Page Follows]

 

48

 

IN WITNESS WHEREOF, the duly authorized representatives of the parties have executed this Agreement as of the date first written above.

 

	
 
    	
PATHEON PHARMACEUTICALS INC.
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Dean Wilson
    
	
 
    	
 
    
	
 
    	
Name:
    	
Dean   Wilson
    
	
 
    	
 
    
	
 
    	
Title:
    	
VP   Corporate Controller
    
	
 
    	
 
    
	
 
    	
SALIX PHARMACEUTICALS, INC
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Rick Scruggs
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
Rick   Scruggs
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
VP   of Business DevelopmentExhibit 10.76

 

Final Execution Draft
 May 21, 2013

 

*** TEXT OMITTED AND SUBMITTED PURSUANT TO CONFIDENTIAL TREATMENT REQUEST

 

Crofelemer Product Agreement

 

(Includes Schedules A to D)

 

This Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agreement dated May 21, 2013 between Patheon Pharmaceuticals Inc., and Salix Pharmaceuticals, Inc., (the “Master Agreement”), and is entered into May 21, 2013 (the “Product Effective Date”), between Patheon Pharmaceuticals Inc., a corporation existing under the laws of the State of Delaware, having a principal place of business at 2110 East Galbraith Road, Cincinnati, OH 45237-1625 (“Patheon Party”) and Salix Pharmaceuticals, Inc., a corporation existing under the laws of the State of California, having a principal place of business at 8510 Colonnade Center Drive, Raleigh, NC, 27615 (“Client Party”).

 

The terms and conditions of the Master Agreement are incorporated herein except to the extent this Product Agreement expressly references a specific provision in the Master Agreement to be modified by this Product Agreement.  All capitalized terms that are used but not defined in this Product Agreement will have the respective meanings given to them in the Master Agreement.

 

The Schedules to this Product Agreement are incorporated into and will be construed in accordance with the terms of this Product Agreement.

 

1.                                      Product List and Specifications (See Schedule A attached hereto).

 

2.                                      Batch Order Quantity, Annual Volume Tiers, and Price (See Schedule B attached hereto)

 

3.                                      Annual Stability Testing and Validation Activities (if applicable) (See Schedule C attached hereto)

 

4.                                      Active Materials, Active Materials Credit Value, and Maximum Credit Value (See Schedule D attached hereto)

 

5.                                      Territory:  United States

 

6.                                      Manufacturing Site:  Patheon Pharmaceuticals Inc., 2110 East Galbraith Road, Cincinnati, OH 45237-1625

 

7.                                      Governing Law:  See Section 13.20(a) of the Master Agreement

 

8.                                      Inflation index for Countries other than the United States:  Not applicable, per Section 4.2(a) of the Master Agreement.

 

9.                                      Currency:  See Section 1.4 of the Master Agreement

 

1

 

10.                               Initial Set Exchange Rate:  Not applicable, per Section 4.2(d) of the Master Agreement.

 

11.                               Initial Product Term:  See Section 8.1 of the Master Agreement

 

12.                               Notices:  See Section 13.9 of the Master Agreement

 

13.                               Other Modifications to the Master Agreement (per Section 1.2 of the Master Agreement).  The parties agree that they will work together in good faith to minimize any delay in the manufacture and delivery of Product that may result if Client is unable to deliver Active Materials in accordance with the lead times described in Section 2.1(f) of the Master Agreement.  Notwithstanding anything to the contrary in Section 5.1(b) of the Master Agreement or any other provision thereof, the parties agree that, during the first [***] months following validation of the Product, Client will not incur any penalties or additional costs as a result of the rescheduling of manufacture or delivery of Product.  Notwithstanding anything to the contrary in Section 2.1(k) of the Master Agreement, Client will be responsible for reasonable expenses incurred by Patheon as a result of Product rejections prior to release by Patheon and additional Patheon expenses incurred in performing the Manufacturing Services for the Product, in each case that are the result of API or process variability that is not reflected in the unit Price for the Product (as described in the “Key Technical Assumptions” set forth in Schedule B hereto).  Testing that is not otherwise contemplated by the “Key Technical Assumptions” or the other terms of this Product Agreement or the Master Agreement, including extra-stage content uniformity and dissolution testing not otherwise contemplated by the “Key Technical Assumptions” or the other terms of this Product Agreement or the Master Agreement, will be at Client’s expense, except to the extent the additional testing is required because of Patheon’s failure to perform the Manufacturing Services in accordance with the terms of this Product Agreement or the Master Agreement (including because of a laboratory or other manufacturing error), which additional testing will be at Patheon’s expense.

 

14.                               Required Percentage and Required Period (per Section 2.1 of the Master Agreement):

 

a)                                     The Required Percentage for a given Year will be, (i) in each of the first two Years of the Product Term, [***]% of Client’s and its Affiliates’ requirements for Product (other than any Authorized Generic Product, but including any Product purchased by Client or its Affiliates for sale to a licensee) offered for sale by Client or its Affiliates, or any licensee of Client or its Affiliates supplied with Product by Client or its Affiliates, in the Territory under NDA 202292, (ii) after the first two Years of the Product Term, [***]% of Client’s and its Affiliates’ requirements for Product (other than any Authorized Generic Product, but including any Product purchased by Client or its Affiliates for sale to a licensee) offered for sale by Client or its Affiliates, or any licensee of Client or Its Affiliates supplied with Product by Client or its Affiliates, in the Territory under NDA 202292 during each Year, and (iii) for each Year during the Product Term in which an Authorized Generic Product is sold in the Territory, [***]% of Client’s and its Affiliates’ requirements (including any Authorized Generic Product purchased by Client or its Affiliates for sale to a licensee) for Authorized Generic

 

*** Confidential Treatment Requested

 

2

 

b)                                     Product offered for sale by Client or its Affiliates or any licensee of Client or its Affiliates supplied with Product by Client or its Affiliates.

 

For purposes of this Section 14, “Authorized Generic Product” means Product sold by Client or its Affiliates or licensees, either directly or through an authorized distributor, in the United States under NDA 202292 as an unbranded generic equivalent of FULYZAQ.

 

c)                                      The Required Period will be the Product Term of this Product Agreement.

 

15.                               Exclusive Arrangement; Right of First Negotiation.

 

a)                                     During the Exclusivity Period, Patheon will not, nor will it permit any of its Affiliates, employees, officers, directors, agents or principals to, conduct any manufacturing services in respect of, or otherwise participate, directly or indirectly, in the development, formulation, testing, quality assurance, evaluation, or commercialization of, crofelemer or any other product derived from the Croton lechleri plant (either alone or in combination with any other compound or ingredient) for its own account or for any person other than Client or, unless and until Client provides notice to the contrary to Patheon, Glenmark Pharma.  If Client desires to enter into an arrangement for the development and manufacture of a product containing crofelemer in combination with another active pharmaceutical ingredient (a “Combination Product Agreement”) during the Exclusivity Period, Client will provide notice to Patheon of such fact (the “Combination Product Notice”).  Patheon will, during the Exclusivity Period, have a first right of negotiation with respect to entering into a Combination Product Agreement with Client, for a period of 60 days following Patheon’s receipt of the Combination Product Notice.  Such right of first negotiation shall be exercisable by Patheon by notice given to Client within 10 days of the date of the Combination Product Notice.  In the event Patheon exercises its right of first negotiation, the parties will promptly begin to negotiate in good faith with respect to the Combination Product Agreement, but neither party shall have any obligation to enter into any agreement unless the parties are able to agree in writing on mutually acceptable terms and conditions at such time.  During such 60 day period, Client will negotiate exclusively with Patheon and will not pursue negotiations with, nor furnish information regarding the development and manufacturing opportunity to, any third party.  If the parties are unable to conclude such an agreement during such 60 day period, Client will be free from and after the end of such 60 day negotiation period to negotiate and enter into Combination Product Agreements with third parties on terms no more favourable to the third party than those offered to Patheon.

 

b)                                     For purposes of this Product Agreement,

 

(i)                                     “Exclusivity Period” means the period of time beginning on the Product Effective Date and ending upon the Generic Launch Date.

 

3

 

(ii)                                  “Generic Launch Date” means the earlier of (A) the date 15 Business Days following the date on which a third party has sold commercial scale quantities of Generic Product in the United States pursuant to a license or authorization from Client or its Affiliates if Client or its Affiliates have not within such 15 Business Day-period commenced the sale of an Authorized Generic Product and (B) the Injunction Failure Date.

 

(iii)                               “Generic Product” means a product that contains crofelemer and has received marketing approval by the FDA for one of the same indications as the Product through an abbreviated new drug application as defined in 21 U.S.C. 355(j) or an application submitted pursuant to 21 U.S.C. 355(b)(2).

 

(iv)                              “Injunction Failure Date” means the date 15 Business Days after the Knowledge Date if, as of the end of the 15 Business Day-period, Client has failed to obtain a temporary restraining order or other preliminary injunctive relief enjoining the sale of the relevant Unauthorized Generic Product; provided that unless Client provides written notice to Patheon prior to the fifth Business Day following the Knowledge Date certifying that it is seeking a temporary restraining order or other preliminary injunctive relief in respect of sales of such Unauthorized Generic Product, the Injunction Failure Date shall be the date five (5) Business Days after the Knowledge Date.

 

(v)                                 “Knowledge Date” means the date on which Client learns or is notified (including by Patheon) of the sale of commercial scale quantities of an Unauthorized Generic Product.

 

(vi)                              “Unauthorized Generic Product” means a Generic Product sold by a third party in the United States without license or authorization from Client or its Affiliates.

 

c)                                      Patheon acknowledges that a breach of Section 15(a) may give rise to irreparable injury to Client and that such injury may not be adequately compensated by damages, that the promises contained in Section 15(a) have been given for the benefit of Client, and that, accordingly, Client may seek and obtain injunctive relief against Patheon, without the posting of bond or other security, to prevent the breach or threatened breach of Section 15(a), in addition to any other legal remedies which may be available to Client.

 

d)                                     Notwithstanding any provision of the Master Agreement to the contrary, the provisions of Sections 10.1 and 10.2(b) thereof will not apply in respect of liability of Patheon for a breach of its commitments made pursuant to this Section 16, and any liability of Patheon for a breach of its commitments made pursuant to this Section 15 will not be taken into account for purposes of determining whether any limitation on liabilities set forth in Section 10.2(b) of the

 

4

 

e)                                      Master Agreement has been met.  The provisions of this Section 15 will survive termination of the Master Agreement and this Product Agreement.

 

16.                               Maximum Amount (per Section 10.2(b) of      the Master Agreement):  The Maximum Amount for purposes of this Product Agreement will be [***]% of revenues to Patheon under this Product Agreement in the Year in which the obligation arises (or the Year immediately prior to or following the Year in which the obligation arises, if revenues to Patheon are greater in the prior or following Year).

 

17.                               Product Manufactured Under Patheon Project Proposal # P-CRP-33321-R4.  The parties agree that (a) Product manufactured by Patheon pursuant to Patheon Project Proposal # P-CRP-33321-R4, dated effective November 14, 2012 (the “Existing Product”), will be deemed (i) to have been manufactured pursuant to the terms of the Master Agreement and this Product Agreement as though the Existing Product had been manufactured at a time when the Master Agreement and this Product Agreement had been executed and delivered by the parties and were in full force and effect and (ii) to be subject to the terms of the Master Agreement and this Product Agreement, and that (b) the provisions of Section 9.3 of the Master Agreement will apply with respect to any Existing Product that is determined by the parties to meet applicable validation requirements.

 

IN WITNESS WHEREOF, the duly authorized representatives of the parties have executed this Product Agreement as of the Product Effective Date set forth above.

 

 

	
 
    	
PATHEON PHARMACEUTICALS INC.
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Dean Wilson
    
	
 
    	
 
    
	
 
    	
Name:   
    	
Dean   Wilson
    
	
 
    	
 
    	
 
    
	
 
    	
Title:   
    	
VP-Corporate   Controller
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
SALIX PHARMACEUTICALS, INC.
    
	
 
    	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Rick Scruggs
    
	
 
    	
 
    
	
 
    	
Name:   
    	
Rick   Scruggs
    
	
 
    	
 
    	
 
    
	
 
    	
Title:   
    	
EVP   of Business Development
    
				

 

*** Confidential Treatment Requested

 

5

 

SCHEDULE A

 

PRODUCT LIST AND SPECIFICATIONS

 

Product List

 

Crofelemer 125 mg tablets

 

Specifications

 

Prior to the start of commercial manufacturing of Product under this Agreement, Client will give Patheon the originally executed copies of the Specifications as approved by the applicable Regulatory Authority.  If the Specifications received are subsequently amended, then Client will give Patheon the revised and originally executed copies of the revised Specifications.  Upon acceptance of the revised Specifications, Patheon will give Client a signed and dated receipt indicating Patheon’s acceptance of the revised Specifications.

 

6

 

Final Execution 
 Draft May 21, 2013

 

SCHEDULE B

 

MINIMUM ORDER QUANTITY, ANNUAL VOLUME, AND PRICE

 

Manufacturing and Packaging Prices

Pricing includes the cost of labour, overhead, raw materials, packaging components and QC testing.

 

Validation Batch (35kg)

 

	
 
    	
 
    	
 
    	
 
    	
Minimum 
    	
 
    	
Price per 60’s Bottle
    
	
Product
    	
 
    	
Annual 
   Quantity 
   (Bottles)
    	
 
    	
Ordering 
   Quantity
    (Bottles)
    	
 
    	
Material 
   Price
    	
 
    	
Conversion 
   Price
    	
 
    	
Full Service 
   Price
    
	
Crofelemer 125mg Tablet
   Single Validation Batch
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    
	
Crofelemer 125mg tablet
   3 Consecutive Validation Batches
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    

 

Small Scale Batch (35kg)

 

	
 
    	
 
    	
 
    	
 
    	
Small Scale
    	
 
    	
Minimum 
    	
 
    	
Price per 60’s Bottle
    
	
Product
    	
 
    	
Small 
   Scale 
   Tier
    	
 
    	
Batch 
   Campaigns 
   per Year
    	
 
    	
Ordering 
   Quantity 
   (Bottles)
    	
 
    	
Material 
   Price
    	
 
    	
Conversion 
   Price
    	
 
    	
Full Service
   Price
    
	
Crofelemer 125mg Tablet
    	
 
    	
1
    	
 
    	
1
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
1
    	
 
    	
2
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Crofelemer 125mg Tablet
    	
 
    	
2
    	
 
    	
1
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
2
    	
 
    	
2
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
2
    	
 
    	
3
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Crofelemer 125mg Tablet
    	
 
    	
3
    	
 
    	
1
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
3
    	
 
    	
2
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
3
    	
 
    	
3
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
3
    	
 
    	
4
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
3
    	
 
    	
5
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Crofelemer 125mg Tablet
    	
 
    	
4
    	
 
    	
1
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
4
    	
 
    	
2
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
4
    	
 
    	
3
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    

 

*** Confidential Treatment Requested

 

7

 

Large Scale Batch (105kg)

 

	
 
    	
 
    	
 
    	
 
    	
Large Scale 
    	
 
    	
Minimum 
    	
 
    	
Price per 60’s Bottle
    
	
Product
    	
 
    	
Large
   Scale 
   Tier
    	
 
    	
Batch 
   Campaigns
   per Year
    	
 
    	
Ordering 
   Quantity
   (Bottles)
    	
 
    	
Material 
   Price
    	
 
    	
Conversion 
   Price
    	
 
    	
Full Service
   Price
    
	
Crofelemer 125mg Tablet
    	
 
    	
1
    	
 
    	
1
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Crofelemer 125mg Tablet
    	
 
    	
2
    	
 
    	
1
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
2
    	
 
    	
2
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
2
    	
 
    	
3
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Crofelemer 125mg Tablet
    	
 
    	
3
    	
 
    	
1
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
3
    	
 
    	
2
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
3
    	
 
    	
3
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
3
    	
 
    	
4
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    	
 
    	
[***]
    

 

Note: Refer to ‘Campaign Assumptions’, for additional detail on the manufacturing and packaging batch campaigns assumed in this proposal.

 

Key Technical Assumptions

 

Below are listed the main assumptions that were utilized by Patheon for quoting this product. Should any of the assumptions change, then the prices will be revised accordingly.

 

Manufacturing Assumptions

 

1.1                               The manufacturing process at Patheon will closely follow the process information provided by Salix and work performed to-date at the site.

 

1.2                               The core tablet weight and manufacturing batch sizes proposed by Patheon are summarized in the following table.

 

	
 
    	
 
    	
Crofelemer 125mg Tablets
    
	
Parameter
    	
 
    	
Small Scale
    	
 
    	
Large Scale
    
	
Tablet weight (mg)
    	
 
    	
[***]
    	
 
    	
[***]
    
	
Batch size at Patheon (tablets)
    	
 
    	
[***]
    	
 
    	
[***]
    
	
Batch size at Patheon (Kg)
    	
 
    	
[***]
    	
 
    	
[***]
    

 

1.3                               Large scale manufacturing assumes Salix will continue to supply Crofelemer Milled Prep with no additional API milling required by Patheon.

 

*** Confidential Treatment Requested

 

8

 

1.4                               Small scale batches will be manufactured in the PDS area and large scale batches will manufactured at commercial scale.

 

1.5                               The following manufacturing equipment train is proposed for Crofelemer Tablets.

 

	
 
    	
 
    	
Equipment
    
	
Process Step
    	
 
    	
(Small Scale 35 kg Batch)
    	
 
    	
(Large Scale 105 kg Batch)
    
	
Blend/Lubricate
    	
 
    	
[***]
    	
 
    	
[***]
    
	
Compress
    	
 
    	
[***]
    	
 
    	
[***]
    
	
Coat
    	
 
    	
[***]
    	
 
    	
[***]
    
	
Print
    	
 
    	
[***]
    	
 
    	
[***]
    

 

Campaign Assumptions

 

The pricing outlined in the ‘Pricing Table’, reflects the campaigns listed below.

 

	
Product Description
    	
 
    	
Manufacturing 
   Campaign 
   (Batches)
    	
 
    	
Packaging 
   Campaign 
   (Batches)
    	
 
    	
Bottle per 
   Packaging 
   Campaign
    
	
Crofelemer 125mg Tablet -
   Single Validation Batch
    	
 
    	
1
    	
 
    	
1
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet -
   3 Consecutive Validation Batches
    	
 
    	
3
    	
 
    	
3
    	
 
    	
[***]
    

 

*** Confidential Treatment Requested

 

9

 

Small Scale Batch (35kg)

 

	
 

Product Description
    	
 
    	
Tier
    	
 
    	
Manufacturing 
   Campaign 
   (Batches)
    	
 
    	
Packaging 
   Campaign 
   (Batches)
    	
 
    	
Bottle per 
   Packaging 
   Campaign
    
	
Crofelemer 125mg Tablet
    	
 
    	
1
    	
 
    	
1
    	
 
    	
1
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
1
    	
 
    	
2
    	
 
    	
2
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
2
    	
 
    	
1
    	
 
    	
1
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
2
    	
 
    	
2
    	
 
    	
2
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
2
    	
 
    	
3
    	
 
    	
3
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
3
    	
 
    	
1
    	
 
    	
1
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
3
    	
 
    	
2
    	
 
    	
2
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
3
    	
 
    	
3
    	
 
    	
3
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
3
    	
 
    	
4
    	
 
    	
4
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
3
    	
 
    	
5
    	
 
    	
5
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
4
    	
 
    	
1
    	
 
    	
1
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
4
    	
 
    	
3
    	
 
    	
3
    	
 
    	
[***]
    

 

Large Scale Batch (35kg)

 

	
Product Description
    	
 
    	
Tier
    	
 
    	
Manufacturing 
   Campaign 
   (Batches)
    	
 
    	
Packaging 

Campaign 

(Batches)
    	
 
    	
Bottle per 
   Packaging 
   Campaign
    
	
Crofelemer 125mg Tablet
    	
 
    	
1
    	
 
    	
1
    	
 
    	
1
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
2
    	
 
    	
1
    	
 
    	
1
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
2
    	
 
    	
2
    	
 
    	
2
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
2
    	
 
    	
3
    	
 
    	
3
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
3
    	
 
    	
1
    	
 
    	
1
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
3
    	
 
    	
2
    	
 
    	
2
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
3
    	
 
    	
3
    	
 
    	
3
    	
 
    	
[***]
    
	
Crofelemer 125mg Tablet
    	
 
    	
3
    	
 
    	
4
    	
 
    	
4
    	
 
    	
[***]
    

 

*** Confidential Treatment Requested

 

10

 

Packaging Assumptions

 

Crofelemer Tablets will be packaged into the configuration listed in the table below.

 

	
60ct Bottles
    	
 
    
	
60ml HDPE round bottle,   WM square, 38mm
    	
 
    
	
38mm COPYRIGHT,   induction seal
    	
 
    
	
Label, 3 color, 1.125”   x 4875”
    	
 
    
	
Topsert
    	
 
    
	
Shipper label (in   house)
    	
 
    
	
pallet, ISPM 15   standard, 48” x 40”
    	
 
    
	
slip sheet, fiber 44” x   52”
    	
 
    

 

1.1.                            Validation batches are assumed to be britestocked and secondary packaged as a two-step process.

 

1.2.                            Material pricing is driven by different label and topsert costs for various tiers.

 

1.3.                            The packaging component specifications assumed in this proposal have been estimated by Patheon. Changes to the specifications will result in review of the final pricing outlined within this proposal.

 

Testing Assumptions

 

1.1.                            Testing for raw materials, packaging components and finished product are based on information provided by Salix and Patheon’s best estimates.

 

1.2.                            Patheon will test each Incoming batch of API for an estimated total of 36 tests per year.

 

1.3.                            Patheon will perform API testing for appearance, ID which includes Assay (gradient HPLC) and IR spectrum. All other test results for the API will be reported on a batch-specific Certificate of Analysis.

 

1.4.                            Finished product release testing includes single analysis of each Appearance, Water Content, ID, Dissolution HPLC Profile — two stage, Content Uniformity, Assay, Related Substance, Acid Resistance, Dissolution (single stage), Acid Hydrolysis, Oligomer Composition, and Micro.

 

1.5.                            It is assumed that QC test methods are fully validated and robust.

 

11

 

1.6.                            Testing labour may be subject to change after the final agreement on testing specifications and requirements.

 

The following cost items are included in the Price for the Products:

 

·                                          Product manufactured and packaged under the Agreement

 

·                                          Standard certificate of analysis (“CON’)

 

·                                          Standard certificate of compliance (“COC”)

 

·                                          GMP required retention samples

 

·                                          Copies of deviation reports

 

·                                          Batch Production Records (“BPR”)/Lot Packaging Records (“LPR”) copies for validation batches, first ten commercial batches, and one commercial batch per Year thereafter

 

·                                          One label copy change per Year

 

·                                          BPR/LPR changes [one change per Year]

 

·                                          Common HPLC/GC columns, reagents, and lab supplies

 

·                                          Copy of the Annual Product Review Report

 

·                                          Product Approval Inspection (‘PAI”) and copy of FDA Report

 

·                                          Simple, routine statistical review

 

·                                          Storage of Production Test Record (“PTR”) batches and other experimental batches for three months

 

·                                          Storage of registration batches and other experimental batches for two years or until Product approval, whichever comes first

 

·                                          Routine sampling and analysis as part of Product manufacture and release

 

·                                          Warehousing of equipment, raw materials, API, and finished goods for normal commercial supply

 

12

 

Final Execution Draft
 May 21, 2013

 

SCHEDULE C

 

ANNUAL STABILITY TESTING

 

Patheon and Client will agree in writing on any stability testing to be performed by Patheon on the Products.  This agreement will specify the commercial and Product stability protocols applicable to the stability testing and the fees payable by Client for this testing. Estimated stability fees are as follows.

 

13

 

SCHEDULE D

 

ACTIVE MATERIALS

 

	
Active Materials
    	
 
    	
Supplier
    
	
Crofelemer
    	
 
    	
·
    

 

ACTIVE MATERIALS CREDIT VALUE

 

The Active Materials Credit Value will be as follows:

 

	
PRODUCT
    	
 
    	
ACTIVE MATERIALS
    	
 
    	
ACTIVE MATERIALS 
   CREDIT VALUE
    
	
Crofelemer
    	
 
    	
Crofelemer
    	
 
    	
Client’s actual cost for Materials not to exceed $[***] per kilogram
    

 

MAXIMUM CREDIT VALUE

 

Patheon’s liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement for the Product in a Year will not exceed, in the aggregate, the maximum credit value set forth below:

 

	
PRODUCT
    	
 
    	
MAXIMUM CREDIT VALUE
    
	
Crofelemer
    	
 
    	
[***] % of revenues per Year   to Patheon under this Product Agreement, up to a maximum of $[***] in the aggregate per Year.
    

 

[End of Product Agreement]

 

*** Confidential Treatment Requested

 

14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}]]